94-16199. Recombinant DNA Research: Actions Under the Guidelines; Notice DEPARTMENT OF HEALTH AND HUMAN SERVICES  

  • [Federal Register Volume 59, Number 127 (Tuesday, July 5, 1994)]
    [Unknown Section]
    [Page 0]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 94-16199]
    
    
    [[Page Unknown]]
    
    [Federal Register: July 5, 1994]
    
    
    _______________________________________________________________________
    
    Part III
    
    
    
    
    
    Department of Health and Human Services
    
    
    
    
    
    _______________________________________________________________________
    
    
    
    National Institutes of Health
    
    
    
    _______________________________________________________________________
    
    
    
    
    Recombinant DNA Research: Actions Under the Guidelines; Notice
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    National Institutes of Health
    
     
    Recombinant DNA Research: Actions Under the Guidelines
    
    AGENCY: National Institutes of Health, PHS, DHHS.
    
    ACTION: Notice of actions under the National Institutes of Health 
    Guidelines for Research Involving Recombinant DNA Molecules (NIH 
    Guidelines).
    
    -----------------------------------------------------------------------
    
    SUMMARY: This notice sets forth four actions to be taken by the 
    Director, National Institutes of Health (NIH), under the May 7, 1986, 
    NIH Guidelines (51 FR 16958).
    
    FOR FURTHER INFORMATION CONTACT: Additional information can be obtained 
    from Dr. Nelson A. Wivel, Director, Office of Recombinant DNA 
    Activities (ORDA), Office of Science Policy and Technology Transfer, 
    National Institutes of Health, Building 31, room 4B11, Bethesda, 
    Maryland 20892, (301) 496-9838.
    
    SUPPLEMENTARY INFORMATION: Today four actions are being promulgated 
    under the NIH Guidelines. These four proposed actions were published 
    for comment in the Federal Register announcements of August 11, 1987 
    (52 FR 29800); April 18, 1988 (53 FR 12752); December 30, 1988 (53 FR 
    53262); April 29, 1991 (56 FR 19776); November 9, 1993 (58 FR 59612); 
    and February 11, 1994 (59 FR 6702). These proposed actions were 
    reviewed and recommended for approval by the NIH Recombinant DNA 
    Advisory Committee (RAC) at its meetings on September 21, 1987; 
    December 3, 1988; January 30, 1989; May 30-31, 1991; December 2-3, 
    1993; and March 3-4, 1994.
        In accordance with Section IV-C-1-b of the NIH Guidelines, these 
    actions have been found to comply with the NIH Guidelines and to 
    present no significant risk to health or the environment.
        A revised version of the NIH Guidelines is published in a separate 
    section of the Federal Register following this announcement. These 
    revised NIH Guidelines differ from the previous version promulgated on 
    May 7, 1986 (51 FR 16958) by incorporating within them the major 
    actions to the NIH Guidelines that were promulgated on August 24, 1987 
    (52 FR 31848); July 29, 1988 (53 FR 28819); October 26, 1988 (53 FR 
    43410); March 13, 1989 (54 FR 10508); March 1, 1990 (55 FR 7438); 
    September 12, 1990 (55 FR 37565); July 18, 1991 (56 FR 33174); October 
    15, 1991 (56 FR 51784); November 21, 1991 (56 FR 58800); January 28, 
    1992 (57 FR 3212); April 22, 1992 (57 FR 14774); August 26, 1992 (57 FR 
    38734); February 18, 1993 (58 FR 9102); April 23, 1993 (58 FR 21738); 
    September 13, 1993 (58 FR 47906); October 18, 1993 (58 FR 53814); and 
    the changes that are promulgated in this announcement.
    
    I. Background Information and Decision on Action Under the NIH 
    Guidelines
    
    A. Amendment to Sections II, III-C, III-D, V, Appendices C-I, and G and 
    Addition of Appendix P, Physical and Biological Containment for 
    Recombinant DNA Research Involving Plants, and Appendix Q, Physical and 
    Biological Containment for Recombinant DNA Research Involving Animals 
    of the NIH Guidelines
    
        The NIH Guidelines were originally developed to cover research in 
    laboratories in which recombinant DNA techniques were used. It is 
    recognized today that these techniques are being used by scientists 
    working with plants and large animals, and that procedures for 
    containment of these plants and animals have not been specifically 
    described in the NIH Guidelines. Institutional Biosafety Committees 
    (IBCs) have requested guidance on the containment procedures that 
    should be recommended for specific experiments with these organisms 
    since they have the responsibility of approving such experiments under 
    containment appropriate for the organisms. The principles of biological 
    safety that are used to categorize experiments involving 
    microorganisms, for example, are equally applicable to plants and 
    animals. These safety procedures have been employed successfully for 
    many years and have been recognized for their efficacy in biological 
    containment.
        Appendices P and Q are the result of several years of meetings and 
    discussions involving research scientists and representatives from 
    university, government, and industrial research sectors with expertise 
    in several disciplines, including plant genetics, plant physiology, 
    plant pathology, entomology, animal (including arthropod and aquatic 
    species) physiology and reproduction, molecular biology, veterinary 
    medicine, and human biomedical research. The Federal agencies involved 
    in the development of Appendices P and Q include the NIH, the National 
    Science Foundation (NSF), and the U.S. Department of Agriculture 
    (USDA).
        The process of developing Appendices P and Q was initiated when the 
    USDA published an Advanced Notice of Proposed USDA Guidelines (USDA 
    Guidelines) in the Federal Register on June 26, 1986 (51 FR 23367). 
    This notice was followed by an announcement by the USDA regarding its 
    intent to propose new guidelines for conducting all phases of research 
    with domestic agriculture species, including both plants and animals 
    modified through the application of genetic engineering techniques, in 
    the Federal Register on December 9, 1986 (51 FR 44397). At that time, 
    the NIH Guidelines did not include specific descriptions for 
    containment conditions for research involving recombinant DNA 
    containing whole plants and animals. The USDA convened a working group 
    composed of university, government, and industrial scientists on 
    December 13-14, 1986, with the purpose of discussing and redrafting 
    guidelines for physical and biological containment of transgenic plant 
    and animal species, and associated microorganisms. This meeting came to 
    be known as the ``Arlington House Workshop.''
        Participants of the ``Arlington House Workshop,'' including former 
    members of the RAC, agreed that the USDA Guidelines should be 
    incorporated into the NIH Guidelines. The workshop participants noted 
    that merging these two documents would offer the distinct advantage of 
    providing a single comprehensive source of information regarding 
    conduct of research involving organisms containing recombinant DNA and 
    plants and animals exposed to microorganisms containing recombinant 
    DNA.
        A staff working group representing the Office of Recombinant DNA 
    Activities, NIH, and the Cooperative State Research Service, USDA, held 
    meetings during the following six months. This working group met with 
    the purpose of revising the containment section and developing a final 
    incorporated document for RAC review, approval by the NIH Director, and 
    incorporation into the NIH Guidelines.
        On June 28, 1987, and July 16, 1987, the RAC appointed the Working 
    Group on Revision of the NIH Guidelines to meet and consider the draft 
    documents, Appendices P and Q, and minor modifications to the NIH 
    Guidelines, that would accommodate the proposed appendices. Appendices 
    P and Q and the proposed revisions to the NIH Guidelines were published 
    for public comment in the Federal Register on August 11, 1987 (52 FR 
    29800). Additional revisions to Appendices P and Q were proposed by the 
    RAC and the Agricultural Research Service, USDA, at the September 17, 
    1987, RAC meeting. These modifications were published for public 
    comment in the Federal Register on December 30, 1988 (53 FR 53262). The 
    RAC Working Group on Transgenic Animals proposed additional 
    modifications to Appendices P and Q which were published for public 
    comment in the Federal Register on April 18, 1988 (53 FR 12752). 
    Further revisions were approved by the RAC at its January 30, 1989, 
    meeting.
        Throughout all of the meetings, discussions, and revisions, the 
    intent of the Federal agencies and interested parties has been to 
    describe working conditions that would minimize the risk to both the 
    researcher and the environment from any possible harm or adverse 
    effects due to the conduct of research involving recombinant DNA 
    containing organisms.
        On June 24, 1994, an Environmental Assessment of Appendices P and Q 
    was completed by the NIH and USDA, and there was a finding of no 
    significant impact. Copies of the Environmental Assessment are 
    available from the Office of Recombinant DNA Activities, National 
    Institutes of Health, Building 31, room 4B11, Bethesda, Maryland 20892, 
    (301) 496-9838.
        The actions are detailed in Section II--Summary of Actions. I 
    accept these recommendations, and the NIH Guidelines will be amended 
    accordingly.
    
    B. Amendment to Sections I-C-1-b-(2) and Deletion of Section III-A-2 of 
    the NIH Guidelines Regarding Deliberate Release
    
        On December 6, 1990, the RAC Planning Subcommittee recommended that 
    the requirement for RAC review of experiments involving deliberate 
    environmental release of organisms containing recombinant DNA be 
    eliminated from the NIH Guidelines. This recommendation reflects the 
    fact that the Federal regulatory agencies, the USDA, and the 
    Environmental Protection Agency (EPA), are responsible for the review 
    and approval of environmental release experiments. The proposed 
    amendment was published for public comment in the Federal Register on 
    April 29, 1991 (56 FR 19776). The RAC reviewed and recommended approval 
    of the proposed amendment at its May 30-31, 1991, meeting.
        The actions are detailed in Section II--Summary of Actions. I 
    accept these recommendations, and the NIH Guidelines will be amended 
    accordingly.
    
    C. Amendments to Sections I, III, IV, and V, and Appendix M of the NIH 
    Guidelines Regarding NIH/ORDA Review and Approval of Certain Categories 
    of Human Gene Transfer Experiments That Qualify for the Accelerated 
    Review Process
    
        On December 3, 1993, and March 3-4, 1994, the Working Group on 
    Accelerated Review Protocols presented an overview of the proposed 
    amendments to the NIH Guidelines. The proposed amendments will: (1) 
    Establish an accelerated review process for certain categories of human 
    gene transfer experiments, (2) allow the NIH/Office of Recombinant DNA 
    Activities to assign the appropriate review category to all human gene 
    transfer proposals that are submitted in compliance with the NIH 
    Guidelines, (3) allow the NIH/Office of Recombinant DNA Activities to 
    approve those categories of human gene transfer experiments that 
    qualify for the accelerated review process in consultation with the 
    Chair and one or more RAC members, as necessary, and (4) exempt certain 
    experiments involving the transfer of recombinant DNA or DNA or RNA 
    derived from recombinant DNA into one or more human subjects which are 
    not covered by Section V-U. All human gene transfer experiments 
    approved by the NIH/Office of Recombinant DNA Activities through the 
    accelerated review process will be provided in a report by the RAC 
    Chair at the next regularly scheduled RAC meeting and will be included 
    in the list of approved experiments which is available from the Office 
    of Recombinant DNA Activities, National Institutes of Health, Building 
    31, Room 4B11, Bethesda, Maryland 20892, (301) 496-9838.
        The proposed amendments were published for public comment in the 
    Federal Register on November 9, 1993 (58 FR 59612) and February 11, 
    1994 (59 FR 6702). The RAC reviewed and unanimously recommended 
    approval of the proposed amendments at its March 3-4, 1994, meeting.
        The actions are detailed in Section II--Summary of Actions. I 
    accept these recommendations, and the NIH Guidelines will be amended 
    accordingly.
    
    D. Amendments to Section V-U of the NIH Guidelines Regarding 
    Recombinant DNA Vaccines
    
        On March 3, 1994, the Working Group on Vaccines presented an 
    overview of the proposed amendment to the footnote in Section V-U. The 
    proposed amendment will define those categories of experiments 
    involving the administration of recombinant DNA vaccines that are 
    exempt from RAC review and NIH and Institutional Biosafety Committee 
    approval.
        The proposed amendment was published for public comments in the 
    Federal Register on February 11, 1994 (59 FR 6702). The proposed 
    amendment was revised by the RAC at its March 3-4, 1994, meeting. The 
    revised amendment was unanimously approved.
        The action is detailed in Section II--Summary of Actions. I accept 
    this recommendation, and the NIH Guidelines will be amended 
    accordingly.
    
    II. Summary of Actions
    
    A. Amendment to Section I, Scope of the NIH Guidelines
    
        The amended version of Section I reads as follows:
    Section I. Scope of the NIH Guidelines
    Section I-A. Purpose
        The purpose of the NIH Guidelines is to specify practices for 
    constructing and handling: (i) Recombinant deoxyribonucleic acid (DNA) 
    molecules, and (ii) organisms and viruses containing recombinant DNA 
    molecules.
        Section I-A-1. Any recombinant DNA experiment, which according to 
    the NIH Guidelines requires approval by the NIH, must be submitted to 
    the NIH or to another Federal agency that has jurisdiction for review 
    and approval. Once approval, or other applicable clearances, has been 
    obtained from a Federal agency other than the NIH (whether the 
    experiment is referred to that agency by the NIH or sent directly there 
    by the submitter), the experiment may proceed without the necessity for 
    NIH review or approval (see exceptions in Sections I-A-2 and I-A-3).
        Section I-A-2. Certain experiments that involve the deliberate 
    transfer of recombinant DNA or DNA or RNA derived from recombinant DNA 
    into one or more human subjects (see Section V-U) shall be considered 
    Major Actions (see Section IV-C-1-b-(1)), and shall require RAC review 
    and NIH Director approval, if determined by NIH/ORDA in consultation 
    with the RAC Chair and/or one or more RAC members, as necessary, to: 
    (i) Represent novel characteristics (e.g., target disease or vector), 
    (ii) represent an uncertain degree of risk to human health or the 
    environment, or (iii) contain information determined to require further 
    public review (see Section III-A-2).
        Section I-A-3. Experiments involving the transfer of recombinant 
    DNA to one or more human subjects that are not considered under Section 
    III-A-2 may qualify for Accelerated Review (see Section III-B-2 and 
    Appendix M-V) and will be considered as Minor Actions (see Section IV-
    C-1-b-(2)-(a)). Actions that qualify for Accelerated Review will be 
    reviewed and approved by NIH/ORDA in consultation with the RAC Chair 
    and/or one or more RAC members, as necessary.
        Certain experiments involving the transfer of recombinant DNA or 
    DNA or RNA derived from recombinant DNA into one or more human subjects 
    (see Section V-U) may be considered exempt from RAC and/or NIH/ORDA 
    review and/or NIH Director approval and only require registration with 
    NIH/ORDA (see Section III-C-7).
    Section I-B. Definition of Recombinant DNA Molecules
        In the context of the NIH Guidelines, recombinant DNA molecules are 
    defined as either: (i) Molecules that are constructed outside living 
    cells by joining natural or synthetic DNA segments to DNA molecules 
    that can replicate in a living cell, or (ii) molecules that result from 
    the replication of those described in (i) above.
        Synthetic DNA segments which are likely to yield a potentially 
    harmful polynucleotide or polypeptide (e.g., a toxin or a 
    pharmacologically active agent) are considered as equivalent to their 
    natural DNA counterpart. If the synthetic DNA segment is not expressed 
    in vivo as a biologically active polynucleotide or polypeptide product, 
    it is exempt from the NIH Guidelines.
        Genomic DNA of plants and bacteria that have acquired a 
    transposable element, even if the latter was donated from a recombinant 
    vector no longer present, are not subject to the NIH Guidelines unless 
    the transposon itself contains recombinant DNA.
    Section I-C. General Applicability
        Section I-C-1. The NIH Guidelines are applicable to:
        Section I-C-1-a. All recombinant DNA research within the United 
    States (U.S.) or its territories that is conducted at or sponsored by 
    an institution that receives any support for recombinant DNA research 
    from the NIH, including research performed directly by the NIH. An 
    individual who receives support for research involving recombinant DNA 
    must be associated with or sponsored by an institution that assumes the 
    responsibilities assigned in the NIH Guidelines.
        Section I-C-1-b. All recombinant DNA research performed abroad: 
    Specifically:
        Section I-C-1-b-(1). Research supported by NIH funds.
        Section I-C-1-b-(2). If they involve testing in humans of materials 
    containing recombinant DNA developed with NIH funds and if the 
    institution that developed those materials sponsors or participates in 
    those projects. Participation includes research collaboration or 
    contractual agreements, not mere provision of research materials.
        Section I-C-1-b-(3). If the host country has established rules for 
    the conduct of recombinant DNA research, then the research must be in 
    compliance with those rules. If the host country does not have such 
    rules, the proposed research must be reviewed and approved by an NIH-
    approved Institutional Biosafety Committee or equivalent review body 
    and accepted in writing by an appropriate national governmental 
    authority of the host country. The safety practices that are employed 
    abroad must be reasonably consistent with the NIH Guidelines.
        Section I-D. General Definitions
        The following terms, which are used throughout the NIH Guidelines, 
    are defined as follows:
        Section I-D-1. An `institution' is any public or private entity 
    (including Federal, state, and local government agencies).
        Section I-D-2. An `Institutional Biosafety Committee' is a 
    committee that: (i) meets the requirements for membership specified in 
    Section IV-B-2, and (ii) reviews, approves, and oversees projects in 
    accordance with the responsibilities defined in Section IV-B-2.
        Section I-D-3. The `Office of Recombinant DNA Activities (ORDA)' is 
    the office within the NIH that is responsible for: (i) Reviewing and 
    coordinating all activities relating to the NIH Guidelines, and (ii) 
    performing other duties as defined in Section IV-C-3.
        Section I-D-4. The `Recombinant DNA Advisory Committee' is the 
    public advisory committee that advises the Department of Health and 
    Human Services (DHHS) Secretary, the DHHS Assistant Secretary for 
    Health, and the NIH Director concerning recombinant DNA research. The 
    RAC shall be constituted as specified in Section IV-C-2.
        Section I-D-5. The `NIH Director' is the Director of the National 
    Institutes of Health, or any other officer or employee of NIH to whom 
    authority has been delegated.
        Section I-D-6. `Deliberate release' is defined as a planned 
    introduction of recombinant DNA-containing microorganisms, plants, or 
    animals into the environment.
        B. Amendment to Section II, Containment, of the NIH Guidelines
        The amended version of Section II reads as follows:
    Section II. Containment
        Effective biological safety programs have been operative in a 
    variety of laboratories for many years. Considerable information 
    already exists about the design of physical containment facilities and 
    selection of laboratory procedures applicable to organisms carrying 
    recombinant DNA (see Section V-A). The existing programs rely upon 
    mechanisms that can be divided into two categories: (i) A set of 
    standard practices that are generally used in microbiological 
    laboratories; and (ii) special procedures, equipment, and laboratory 
    installations that provide physical barriers that are applied in 
    varying degrees according to the estimated biohazard. Four biosafety 
    levels are described in Appendix G. These biosafety levels consist of 
    combinations of laboratory practices and techniques, safety equipment, 
    and laboratory facilities appropriate for the operations performed and 
    are based on the potential hazards imposed by the agents used and for 
    the laboratory function and activity. Biosafety Level 4 provides the 
    most stringent containment conditions, Biosafety Level 1 the least 
    stringent.
        Experiments involving recombinant DNA lend themselves to a third 
    containment mechanism, namely, the application of highly specific 
    biological barriers. Natural barriers exist that limit either: (i) The 
    infectivity of a vector or vehicle (plasmid or virus) for specific 
    hosts, or (ii) its dissemination and survival in the environment. 
    Vectors, which provide the means for recombinant DNA and/or host cell 
    replication, can be genetically designed to decrease, by many orders of 
    magnitude, the probability of dissemination of recombinant DNA outside 
    the laboratory (see Appendix I).
        Since these three means of containment are complementary, different 
    levels of containment can be established that apply various 
    combinations of the physical and biological barriers along with a 
    constant use of standard practices. Categories of containment are 
    considered separately in order that such combinations can be 
    conveniently expressed in the NIH Guidelines.
        Physical containment conditions within laboratories, described in 
    Appendix G, may not always be appropriate for all organisms because of 
    their physical size, the number of organisms needed for an experiment, 
    or the particular growth requirements of the organism. Likewise, 
    biological containment for microorganisms described in Appendix I may 
    not be appropriate for all organisms, particularly higher eukaryotic 
    organisms. However, significant information exists about the design of 
    research facilities and experimental procedures that are applicable to 
    organisms containing recombinant DNA that is either integrated into the 
    genome or into microorganisms associated with the higher organism as a 
    symbiont, pathogen, or other relationship. This information describes 
    facilities for physical containment of organisms used in non-
    traditional laboratory settings and special practices for limiting or 
    excluding the unwanted establishment, transfer of genetic information, 
    and dissemination of organisms beyond the intended location, based on 
    both physical and biological containment principles. Research conducted 
    in accordance with these conditions effectively confines the organism.
        For research involving plants, four biosafety levels (BL1-P through 
    BL4-P) are described in Appendix P. BL1-P is designed to provide a 
    moderate level of containment for experiments for which there is 
    convincing biological evidence that precludes the possibility of 
    survival, transfer, or dissemination of recombinant DNA into the 
    environment, or in which there is no recognizable and predictable risk 
    to the environment in the event of accidental release. BL2-P is 
    designed to provide a greater level of containment for experiments 
    involving plants and certain associated organisms in which there is a 
    recognized possibility of survival, transmission, or dissemination of 
    recombinant DNA containing organisms, but the consequence of such an 
    inadvertent release has a predictably minimal biological impact. BL3-P 
    and BL4-P describe additional containment conditions for research with 
    plants and certain pathogens and other organisms that require special 
    containment because of their recognized potential for significant 
    detrimental impact on managed or natural ecosystems. BL1-P relies upon 
    accepted scientific practices for conducting research in most ordinary 
    greenhouse or growth chamber facilities and incorporates accepted 
    procedures for good pest control and cultural practices. BL1-P 
    facilities and procedures provide a modified and protected environment 
    for the propagation of plants and microorganisms associated with the 
    plants and a degree of containment that adequately controls the 
    potential for release of biologically viable plants, plant parts, and 
    microorganisms associated with them. BL2-P and BL3-P rely upon accepted 
    scientific practices for conducting research in greenhouses with 
    organisms infecting or infesting plants in a manner that minimizes or 
    prevents inadvertent contamination of plants within or surrounding the 
    greenhouse. BL4-P describes facilities and practices known to provide 
    containment of certain exotic plant pathogens.
        For research involving animals, which are of a size or have growth 
    requirements that preclude the use of conventional primary containment 
    systems used for small laboratory animals, four biosafety levels (BL1-N 
    through BL4-N) are described in Appendix Q. BL1-N describes containment 
    for animals that have been modified by stable introduction of 
    recombinant DNA, or DNA derived therefrom, into the germ-line 
    (transgenic animals) and experiments involving viable recombinant DNA-
    modified microorganisms and is designed to eliminate the possibility of 
    sexual transmission of the modified genome or transmission of 
    recombinant DNA-derived viruses known to be transmitted from animal 
    parent to offspring only by sexual reproduction. Procedures, practices, 
    and facilities follow classical methods of avoiding genetic exchange 
    between animals. BL2-N describes containment which is used for 
    transgenic animals associated with recombinant DNA-derived organisms 
    and is designed to eliminate the possibility of vertical or horizontal 
    transmission. Procedures, practices, and facilities follow classical 
    methods of avoiding genetic exchange between animals or controlling 
    arthropod transmission. BL3-N and BL4-N describe higher levels of 
    containment for research with certain transgenic animals involving 
    agents which pose recognized hazard.
        In constructing the NIH Guidelines, it was necessary to define 
    boundary conditions for the different levels of physical and biological 
    containment and for the classes of experiments to which they apply. 
    These definitions do not take into account all existing and anticipated 
    information on special procedures that will allow particular 
    experiments to be conducted under different conditions than indicated 
    here without affecting risk. Individual investigators and Institutional 
    Biosafety Committees are urged to devise simple and more effective 
    containment procedures and to submit recommended changes in the NIH 
    Guidelines to permit the use of these procedures.''
    
    C. Amendment to Section III, Experiments Covered by the NIH Guidelines
    
        The previous version of Section III-A-2 will be deleted as follows:
        Section III-A-2. Deliberate release into the environment of any 
    organism containing recombinant DNA except those listed below. The term 
    `deliberate release' is defined as a planned introduction of 
    recombinant DNA-containing microorganisms, plants, or animals into the 
    environment.
        Section III-A-2-a. Introduction conducted under conditions 
    considered to be accepted scientific practices in which there is 
    adequate evidence of biological and/or physical control of the 
    recombinant DNA-containing organisms. The nature of such evidence is 
    described in Appendix L.
        Section III-A-2-b. Deletion derivatives and single base changes not 
    otherwise covered by the NIH Guidelines.
        Section III-A-2-c. For extrachromosomal elements and microorganisms 
    (including viruses), rearrangements and amplifications within a single 
    genome. Rearrangements involving the introduction of DNA from different 
    strains of the same species would not be covered by this exemption.''
        The amended version of Section III reads as follows:
        Section III. Experiments Covered by the NIH Guidelines.
        This section describes five categories of experiments involving 
    recombinant DNA: (i) Those that require RAC review and NIH and 
    Institutional Biosafety Committee approval before initiation (see 
    Section III-A), (ii) those that require NIH/ORDA and Institutional 
    Biosafety Committee approval before initiation (see Section III-B); 
    (iii) those that require Institutional Biosafety Committee approval 
    before initiation (see Section III-C), (iv) those that require 
    Institutional Biosafety Committee notification simultaneous with 
    initiation (see Section III-D), and (v) those that are exempt from the 
    NIH Guidelines (see Section III-E).
    
        Note: If an experiment falls into either Section III-A or 
    Section III-B and one of the other categories, the rules pertaining 
    to Section III-A or Section III-B shall be followed. If an 
    experiment falls into Section III-E and into either Sections III-C 
    or III-D categories as well, the experiment is considered exempt 
    from the NIH Guidelines.
    
        Any change in containment level, which is different from those 
    specified in the NIH Guidelines, may not be initiated without the 
    express approval of NIH/ORDA (see Minor Actions, Section IV-C-1-b-(2) 
    and its subsections).
    Section III-A. Experiments That Require Institutional Biosafety 
    Committee Approval, RAC Review, and NIH Approval Before Initiation
        Experiments in this category are considered Major Actions (see 
    Section IV-C-1-b-(1)) and cannot be initiated without submission of 
    relevant information on the proposed experiment to the Office of 
    Recombinant DNA Activities, National Institutes of Health, Building 31, 
    Room 4B11, Bethesda, Maryland 20892, (301) 496-9838, the publication of 
    the proposal in the Federal Register for 15 days of comment, reviewed 
    by the RAC, and specific approval by the NIH (not applicable for 
    Expedited Review single patient human gene transfer experiments 
    considered under Appendix M-VI). The containment conditions for such 
    experiments will be recommended by the RAC and set by the NIH at the 
    time of approval. Such experiments require Institutional Biosafety 
    Committee approval before initiation. Specific experiments already 
    approved are included in Appendix D which may be obtained from the 
    Office of Recombinant DNA Activities, National Institutes of Health, 
    Building 31, Room 4B11, Bethesda, Maryland 20892, (301) 496-9838.
        Section III-A-1. Deliberate transfer of a drug resistance trait to 
    microorganisms that are not known to acquire the trait naturally (see 
    Section V-B), if such acquisition could compromise the use of the drug 
    to control disease agents in humans, veterinary medicine, or 
    agriculture.
        Section III-A-2. Certain experiments involving the deliberate 
    transfer of recombinant DNA or DNA or RNA derived from recombinant DNA 
    into one or more human subjects (see Section V-U) shall be considered 
    Major Actions (see Section IV-C-1-b-(1) and Appendix M-III), and shall 
    require RAC review and NIH Director approval, if determined by NIH/
    ORDA, in consultation with the RAC Chair and one or more RAC members, 
    as necessary, to: (i) represent novel characteristics (e.g., target 
    disease or vector), (ii) represent an uncertain degree of risk to human 
    health or the environment, or (iii) contain information determined to 
    require further public review. The requirement for RAC review shall not 
    be considered to preempt any other required review or approval of 
    experiments with one or more human subjects. Relevant Institutional 
    Biosafety Committee and Institutional Review Board reviews and 
    approvals of the proposal should be completed before submission to NIH. 
    Certain experiments involving deliberate transfer of recombinant DNA or 
    DNA or RNA derived from recombinant DNA into one or more human subjects 
    may qualify for the Accelerated Review process (see Section III-B-2). 
    Certain categories of experiments involving the deliberate transfer of 
    recombinant DNA or DNA or RNA derived from recombinant DNA into one or 
    more human subjects and that are not covered by Section V-U, may be 
    considered exempt from RAC and/or NIH/ORDA review and/or NIH Director 
    approval and only require registration with NIH/ORDA (see Section III-
    C-7).
    Section III-B. Experiments That Require NIH/ORDA and Institutional 
    Biosafety Committee Approval Before Initiation
    Section III-B-1. Experiments Involving the Cloning of Toxin Molecules 
    with LD50 of Less Than 100 Nanograms per Kilogram Body Weight
        Deliberate formation of recombinant DNA containing genes for the 
    biosynthesis of toxin molecules lethal for vertebrates at an LD50 
    of less than 100 nanograms per kilogram body weight (e.g., microbial 
    toxins such as the botulinum toxins, tetanus toxin, diphtheria toxin, 
    and Shigella dysenteriae neurotoxin). Specific approval has been given 
    for the cloning in Escherichia coli K-12 of DNA containing genes coding 
    for the biosynthesis of toxic molecules which are lethal to vertebrates 
    at 100 nanograms to 100 micrograms per kilogram body weight. Specific 
    experiments already approved under this section may be obtained from 
    the Office of Recombinant DNA Activities, National Institutes of 
    Health, Building 31, Room 4B11, Bethesda, Maryland 20892, (301) 496-
    9838.
        Section III-B-1-(a). Experiments in this category cannot be 
    initiated without submission of relevant information on the proposed 
    experiment to NIH/ORDA. The containment conditions for such experiments 
    will be determined by NIH/ORDA in consultation with ad hoc experts. 
    Such experiments require Institutional Biosafety Committee approval 
    before initiation (see Section IV-B-2-b-(1)).
    Section III-B-2. Accelerated Review of Human Gene Transfer Experiments
        As determined by NIH/ORDA, in consultation with the RAC Chair and 
    one or more RAC members, as necessary, certain categories of human gene 
    transfer experiments may be considered as Minor Actions and qualify for 
    Accelerated Review and approval (see Section IV-C-1-b-(2)-(a), Appendix 
    M-III-A, and Appendix M- V). The RAC Chair will present a report of all 
    NIH/ORDA approved human gene transfer protocols at the next regularly 
    scheduled RAC meeting. If NIH/ORDA determines that an experiment does 
    not qualify for the Accelerated Review process, the Principal 
    Investigator must submit the proposal for full RAC review  8 
    weeks prior to the next scheduled RAC meeting (See Section III-A-2).
    Section III-B-3. Minor Modifications to Human Gene Transfer Experiments
        A minor modification in a human gene transfer protocol is a 
    modification that does not significantly alter the basic design of the 
    protocol and that does not increase risk to human subjects or the 
    environment. After approval has been obtained by the relevant 
    Institutional Biosafety Committee and Institutional Review Board, NIH/
    ORDA will consider the change in consultation with the RAC Chair and 
    one or more RAC members, as necessary. Submit minor modifications to 
    the Office of Recombinant DNA Activities, National Institutes of 
    Health, Building 31, Room 4B11, Bethesda, Maryland 20892, (301) 496-
    9838. The RAC Chair will provide a report on any such approvals at the 
    next regularly scheduled RAC meeting.
    Section III-C. Experiments That Require Institutional Biosafety 
    Committee Approval Before Initiation
        Prior to the initiation of an experiment that falls into this 
    category, the Principal Investigator must submit a registration 
    document to the Institutional Biosafety Committee which contains the 
    following information: (i) The source(s) of DNA; (ii) the nature of the 
    inserted DNA sequences; (iii) the host(s) and vector(s) to be used; 
    (iv) if an attempt will be made to obtain expression of a foreign gene, 
    and if so, indicate the protein that will be produced; and (v) the 
    containment conditions that will be implemented as specified in the NIH 
    Guidelines. For experiments in this category, the registration document 
    shall be dated, signed by the Principal Investigator, and filed with 
    the Institutional Biosafety Committee. The Institutional Biosafety 
    Committee shall review and approve all experiments in this category 
    prior to their initiation. Requests to decrease the level of 
    containment specified for experiments in this category will be 
    considered by NIH (see Section IV-C-1-b-(2)-(c)).
    Section III-C-1. Experiments Using Human or Animal Pathogens (Class 2, 
    Class 3, Class 4, or Class 5 Agents (See Section V-A) as Host-Vector 
    Systems
        Section III-C-1-a. Experiments involving the introduction of 
    recombinant DNA into Class 2 agents shall be conducted at Biosafety 
    Level (BL) 2 containment. Experiments with such agents shall be 
    conducted with whole animals at BL2 or BL2-N (Animals) containment.
        Section III-C-1-b. Experiments involving the introduction of 
    recombinant DNA into Class 3 agents shall be conducted at BL3 
    containment. Experiments with such agents shall be conducted with whole 
    animals at BL3 or BL3-N containment.
        Section III-C-1-c. Experiments involving the introduction of 
    recombinant DNA into Class 4 agents shall be conducted at BL4 
    containment. Experiments with such agents shall be conducted with whole 
    animals at BL4 or BL4-N containment.
        Section III-C-1-d. Containment conditions for experiments involving 
    the introduction of recombinant DNA into Class 5 agents shall be set on 
    a case-by-case basis following NIH/ORDA review. A U.S. Department of 
    Agriculture permit is required for work with Class 5 agents (see 
    Sections V-R and V-T). Experiments with such agents shall be conducted 
    with whole animals at BL4 or BL4-N containment.
    Section III-C-2. Experiments in Which DNA From Human or Animal 
    Pathogens (Class 2, Class 3, Class 4, or Class 5 Agents (See Section V-
    A) is Cloned Into Nonpathogenic Prokaryotic or Lower Eukaryotic Host-
    Vector Systems
        Section III-C-2-a. Experiments in which DNA from Class 2 or Class 3 
    agents (see Section V-A) is transferred into nonpathogenic prokaryotes 
    or lower eukaryotes may be performed under BL2 containment. Experiments 
    in which DNA from Class 4 agents is transferred into nonpathogenic 
    prokaryotes or lower eukaryotes may be performed under BL2 containment 
    after demonstration that only a totally and irreversibly defective 
    fraction of the agent's genome is present in a given recombinant. In 
    the absence of such a demonstration, BL4 containment shall be used. The 
    Institutional Biosafety Committee may approve the specific lowering of 
    containment for particular experiments to BL1. Many experiments in this 
    category are exempt from the NIH Guidelines (see Section III-E). 
    Experiments involving the formation of recombinant DNA for certain 
    genes coding for molecules toxic for vertebrates require NIH/ORDA 
    approval (see Section III-B-1) or shall be conducted under NIH 
    specified conditions as described in Appendix F.
        Section III-C-2-b. Containment conditions for experiments in which 
    DNA from Class 5 agents is transferred into nonpathogenic prokaryotes 
    or lower eukaryotes shall be determined by NIH/ORDA following a case-
    by-case review. A U.S. Department of Agriculture permit is required for 
    work with Class 5 agents (see Sections V-R and V-T).
    Section III-C-3. Experiments Involving the Use of Infectious Animal or 
    Plant DNA or RNA Viruses or Defective Animal or Plant DNA or RNA 
    Viruses in the Presence of Helper Virus in Tissue Culture Systems
        Caution: Special care should be used in the evaluation of 
    containment levels for experiments which are likely to either enhance 
    the pathogenicity (e.g., insertion of a host oncogene) or to extend the 
    host range (e.g., introduction of novel control elements) of viral 
    vectors under conditions that permit a productive infection. In such 
    cases, serious consideration should be given to increasing physical 
    containment by at least one level.
    
        Note: Recombinant DNA or RNA molecules derived therefrom, which 
    contain less than two-thirds of the genome of any eukaryotic virus 
    (all viruses from a single Family (see Section V-Q) being considered 
    identical (see Section V-S), are considered defective and may be 
    used in the absence of helper under the conditions specified in 
    Section III-D-1.
    
        Section III-C-3-a. Experiments involving the use of infectious or 
    defective Class 2 animal viruses (see Section V-A, Appendix B-II, and 
    Appendix B-II-E) in the presence of helper virus may be conducted at 
    BL2.
        Section III-C-3-b. Experiments involving the use of infectious or 
    defective Class 3 animal viruses (see Section V-A and Appendix B-III-D) 
    in the presence of helper virus may be conducted at BL3.
        Section III-C-3-c. Experiments involving the use of infectious or 
    defective Class 4 animal viruses (see Section V-A and Appendix B-IV-D) 
    in the presence of helper virus may be conducted at BL4.
        Section III-C-3-d. Experiments involving the use of infectious or 
    defective Class 5 viruses (see Section V-A and Appendix B-V) in the 
    presence of helper virus shall be determined on a case-by-case basis 
    following NIH/ORDA review. A U.S. Department of Agriculture permit is 
    required for work with Class 5 agents (see Sections V-R and V-T).
        Section III-C-3-e. Experiments involving the use of infectious or 
    defective animal or plant viruses in the presence of helper virus are 
    not covered in Sections III-C-3-a through III-C-3-d and may be 
    conducted at BL1.
    Section III-C-4. Experiments Involving Whole Animals
        This section covers experiments involving whole animals in which 
    the animal's genome has been altered by stable introduction of 
    recombinant DNA, or DNA derived therefrom, into the germ-line 
    (transgenic animals) and experiments involving viable recombinant DNA-
    modified microorganisms tested on whole animals. For the latter, other 
    than viruses which are only vertically transmitted, the experiments may 
    not be conducted at BL1-N containment. A minimum containment of BL2 or 
    BL2-N is required.
        Caution--Special care should be used in the evaluation of 
    containment conditions for some experiments with transgenic animals. 
    For example, such experiments might lead to the creation of novel 
    mechanisms or increased transmission of a recombinant pathogen or 
    production of undesirable traits in the host animal. In such cases, 
    serious consideration should be given to increasing the containment 
    conditions.
        Section III-C-4-a. Recombinant DNA, or DNA or RNA molecules derived 
    therefrom, from any source except for greater than two-thirds of 
    eukaryotic viral genome may be transferred to any non-human vertebrate 
    or any invertebrate organism and propagated under conditions of 
    physical containment comparable to BL1 or BL1-N and appropriate to the 
    organism under study (see Section V-B).
        Animals that contain sequences from viral vectors, which do not 
    lead to transmissible infection either directly or indirectly as a 
    result of complementation or recombination in animals, may be 
    propagated under conditions of physical containment comparable to BL1 
    or BL1-N and appropriate to the organism under study. Experiments 
    involving the introduction of other sequences from eukaryotic viral 
    genomes into animals are covered under Section III-C-4-b. For 
    experiments involving recombinant DNA-modified Class 2, 3, 4, or 5 
    organisms, see Section V-A. It is important that the investigator 
    demonstrate that the fraction of the viral genome being utilized does 
    not lead to productive infection. A U.S. Department of Agriculture 
    permit is required for work with Class 5 agents (see Section V-R and V-
    T).
        Section III-C-4-b. For experiments involving recombinant DNA, or 
    DNA or RNA derived therefrom, involving whole animals, including 
    transgenic animals, and not covered by Sections III-C-1 or III-C-4-a, 
    the appropriate containment shall be determined by the Institutional 
    Biosafety Committee.
    Section III-C-5. Experiments Involving Whole Plants
        Experiments to genetically engineer plants by recombinant DNA 
    methods, to use such plants for other experimental purposes (e.g., 
    response to stress), to propagate such plants, or to use plants 
    together with microorganisms or insects containing recombinant DNA, may 
    be conducted under the containment conditions described in Sections 
    III-C-5-a through III-C-5-e. If experiments involving whole plants are 
    not described in Section III-C-5 and do not fall under Sections III-A, 
    III-B, or III-E, they are included in Section III-D.
    
        Note. For recombinant DNA experiments falling under Sections 
    III-C-5-a through III-C-5-d, physical containment requirements may 
    be reduced to the next lower level by appropriate biological 
    containment practices, such as conducting experiments on a virus 
    with an obligate insect vector in the absence of that vector or 
    using a genetically attenuated strain.
    
        Section III-C-5-a. BL3-P (Plants) or BL2-P + biological containment 
    is recommended for experiments involving most exotic (see Section V-W) 
    infectious agents with recognized potential for serious detrimental 
    impact on managed or natural ecosystems when recombinant DNA techniques 
    are associated with whole plants.
        Section III-C-5-b. BL3-P or BL2-P + biological containment is 
    recommended for experiments involving plants containing cloned genomes 
    of readily transmissible exotic (see Section V-W) infectious agents 
    with recognized potential for serious detrimental effects on managed or 
    natural ecosystems in which there exists the possibility of 
    reconstituting the complete and functional genome of the infectious 
    agent by genomic complementation in planta.
        Section III-C-5-c. BL4-P containment is recommended for experiments 
    with a small number of readily transmissible exotic (see Section V-W) 
    infectious agents, such as the soybean rust fungus (Phakospora 
    pachyrhizi) and maize streak or other viruses in the presence of their 
    specific arthropod vectors, that have the potential of being serious 
    pathogens of major U.S. crops.
        Section III-C-5-d. BL3-P containment is recommended for experiments 
    involving sequences encoding potent vertebrate toxins introduced into 
    plants or associated organisms. Recombinant DNA containing genes for 
    the biosynthesis of toxin molecules lethal for vertebrates at an 
    LD50 of <100 nanograms="" per="" kilogram="" body="" weight="" fall="" under="" section="" iii-b-1="" and="" require="" nih/orda="" and="" institutional="" biosafety="" committee="" approval="" before="" initiation.="" section="" iii-c-5-e.="" bl3-p="" or="" bl2-p="" +="" biological="" containment="" is="" recommended="" for="" experiments="" with="" microbial="" pathogens="" of="" insects="" or="" small="" animals="" associated="" with="" plants="" if="" the="" recombinant="" dna-modified="" organism="" has="" a="" recognized="" potential="" for="" serious="" detrimental="" impact="" on="" managed="" or="" natural="" ecosystems.="" section="" iii-c-6.="" experiments="" involving="" more="" than="" 10="" liters="" of="" culture="" the="" appropriate="" containment="" will="" be="" decided="" by="" the="" institutional="" biosafety="" committee.="" where="" appropriate,="" appendix="" k,="" physical="" containment="" for="" large="" scale="" uses="" of="" organisms="" containing="" recombinant="" dna="" molecules,="" shall="" be="" used.="" appendix="" k="" describes="" containment="" conditions="" good="" large="" scale="" practice="" through="" bl3-large="" scale.="" section="" iii-c-7.="" human="" gene="" transfer="" experiments="" not="" covered="" by="" sections="" iii-a-2,="" iii-b-2,="" iii-b-3,="" and="" not="" considered="" exempt="" under="" section="" v-u="" certain="" experiments="" involving="" the="" transfer="" of="" recombinant="" dna="" or="" dna="" or="" rna="" derived="" from="" recombinant="" dna="" into="" one="" or="" more="" human="" subjects="" that="" are="" not="" covered="" by="" sections="" iii-a-2,="" iii-b-2,="" iii-b-3,="" and="" that="" are="" not="" considered="" exempt="" under="" section="" v-u="" must="" be="" registered="" with="" nih/orda.="" the="" relevant="" institutional="" biosafety="" committee="" and="" institutional="" review="" board="" must="" review="" and="" approve="" all="" experiments="" in="" this="" category="" prior="" to="" their="" initiation.="" section="" iii-d.="" experiments="" that="" require="" institutional="" biosafety="" committee="" notice="" simultaneous="" with="" initiation="" experiments="" not="" included="" in="" sections="" iii-a,="" iii-b,="" iii-c,="" iii-e,="" and="" their="" subsections="" are="" considered="" in="" section="" iii-d.="" all="" such="" experiments="" may="" be="" conducted="" at="" bl1="" containment.="" for="" experiments="" in="" this="" category,="" a="" registration="" document="" (see="" section="" iii-c)="" shall="" be="" dated="" and="" signed="" by="" the="" investigator="" and="" filed="" with="" the="" local="" institutional="" biosafety="" committee="" at="" the="" time="" the="" experiment="" is="" initiated.="" the="" institutional="" biosafety="" committee="" reviews="" and="" approves="" all="" such="" proposals,="" but="" institutional="" biosafety="" committee="" review="" and="" approval="" prior="" to="" initiation="" of="" the="" experiment="" is="" not="" required="" (see="" section="" iv-a).="" for="" example,="" experiments="" in="" which="" all="" components="" derived="" from="" non-pathogenic="" prokaryotes="" and="" non-pathogenic="" lower="" eukaryotes="" fall="" under="" section="" iii-d="" and="" may="" be="" conducted="" at="" bl1="" containment.="" section="" iii-d-1.="" experiments="" involving="" the="" formation="" of="" recombinant="" dna="" molecules="" containing="" no="" more="" than="" two-thirds="" of="" the="" genome="" of="" any="" eukaryotic="" virus="" recombinant="" dna="" molecules="" containing="" no="" more="" than="" two-thirds="" of="" the="" genome="" of="" any="" eukaryotic="" virus="" (all="" viruses="" from="" a="" single="" family="" (see="" section="" v-q)="" being="" considered="" identical="" (see="" section="" v-s))="" may="" be="" propagated="" and="" maintained="" in="" cells="" in="" tissue="" culture="" using="" bl1="" containment.="" for="" such="" experiments,="" it="" must="" be="" demonstrated="" that="" the="" cells="" lack="" helper="" virus="" for="" the="" specific="" families="" of="" defective="" viruses="" being="" used.="" if="" helper="" virus="" is="" present,="" procedures="" specified="" under="" section="" iii-c-3="" should="" be="" used.="" the="" dna="" may="" contain="" fragments="" of="" the="" genome="" of="" viruses="" from="" more="" than="" one="" family="" but="" each="" fragment="" shall="" be="" less="" than="" two-thirds="" of="" a="" genome.="" section="" iii-d-2.="" experiments="" involving="" whole="" plants="" this="" section="" covers="" experiments="" involving="" recombinant="" dna-modified="" whole="" plants,="" and/or="" experiments="" involving="" recombinant="" dna-modified="" organisms="" associated="" with="" whole="" plants,="" except="" those="" that="" fall="" under="" section="" iii-a,="" iii-b,="" iii-c,="" or="" iii-e.="" it="" should="" be="" emphasized="" that="" knowledge="" of="" the="" organisms="" and="" judgment="" based="" on="" accepted="" scientific="" practices="" should="" be="" used="" in="" all="" cases="" in="" selecting="" the="" appropriate="" level="" of="" containment.="" for="" example,="" if="" the="" genetic="" modification="" has="" the="" objective="" of="" increasing="" pathogenicity="" or="" converting="" a="" non-pathogenic="" organism="" into="" a="" pathogen,="" then="" a="" higher="" level="" of="" containment="" may="" be="" appropriate="" depending="" on="" the="" organism,="" its="" mode="" of="" dissemination,="" and="" its="" target="" organisms.="" by="" contrast,="" a="" lower="" level="" of="" containment="" may="" be="" appropriate="" for="" small="" animals="" associated="" with="" many="" types="" of="" recombinant="" dna-modified="" plants.="" section="" iii-d-2-a.="" bl1-p="" is="" recommended="" for="" all="" experiments="" with="" recombinant="" dna-containing="" plants="" and="" plant-associated="" microorganisms="" not="" covered="" in="" section="" iii-d-2-b="" or="" other="" sections="" of="" the="" nih="" guidelines.="" examples="" of="" such="" experiments="" are="" those="" involving="" recombinant="" dna-modified="" plants="" that="" are="" not="" noxious="" weeds="" or="" that="" cannot="" interbreed="" with="" noxious="" weeds="" in="" the="" immediate="" geographic="" area,="" and="" experiments="" involving="" whole="" plants="" and="" recombinant="" dna-modified="" non-exotic="" (see="" section="" v-w)="" microorganisms="" that="" have="" no="" recognized="" potential="" for="" rapid="" and="" widespread="" dissemination="" or="" for="" serious="" detrimental="" impact="" on="" managed="" or="" natural="" ecosystems="" (e.g.,="" rhizobium="" spp.="" and="" agrobacterium="" spp.).="" section="" iii-d-2-b.="" bl2-p="" or="" bl1-p="" +="" biological="" containment="" is="" recommended="" for="" the="" following="" experiments:="" section="" iii-d-2-b-(1).="" plants="" modified="" by="" recombinant="" dna="" that="" are="" noxious="" weeds="" or="" can="" interbreed="" with="" noxious="" weeds="" in="" the="" immediate="" geographic="" area.="" section="" iii-d-2-b-(2).="" plants="" in="" which="" the="" introduced="" dna="" represents="" the="" complete="" genome="" of="" a="" non-exotic="" infectious="" agent="" (see="" section="" v-w).="" section="" iii-d-2-b-(3).="" plants="" associated="" with="" recombinant="" dna-="" modified="" non-exotic="" microorganisms="" that="" have="" a="" recognized="" potential="" for="" serious="" detrimental="" impact="" on="" managed="" or="" natural="" ecosystems="" (see="" section="" v-w).="" section="" iii-d-2-b-(4).="" plants="" associated="" with="" recombinant="" dna-="" modified="" exotic="" microorganisms="" that="" have="" no="" recognized="" potential="" for="" serious="" natural="" ecosystems="" (see="" section="" v-w).="" section="" iii-d-2-b-(5).="" experiments="" with="" recombinant="" dna-modified="" arthropods="" or="" small="" animals="" associated="" with="" plants,="" or="" with="" arthropods="" or="" small="" animals="" with="" recombinant="" dna-modified="" microorganisms="" associated="" with="" them="" if="" the="" recombinant="" dna-modified="" microorganisms="" have="" no="" recognized="" potential="" for="" serious="" detrimental="" impact="" on="" managed="" or="" natural="" ecosystems="" (see="" section="" v-w).="" section="" iii-e.="" exempt="" experiments="" the="" following="" recombinant="" dna="" molecules="" are="" exempt="" from="" the="" nih="" guidelines="" and="" registration="" with="" the="" institutional="" biosafety="" committee="" is="" not="" required:="" section="" iii-e-1.="" those="" that="" are="" not="" in="" organisms="" or="" viruses.="" section="" iii-e-2.="" those="" that="" consist="" entirely="" of="" dna="" segments="" from="" a="" single="" nonchromosomal="" or="" viral="" dna="" source,="" though="" one="" or="" more="" of="" the="" segments="" may="" be="" a="" synthetic="" equivalent.="" section="" iii-e-3.="" those="" that="" consist="" entirely="" of="" dna="" from="" a="" prokaryotic="" host="" including="" its="" indigenous="" plasmids="" or="" viruses="" when="" propagated="" only="" in="" that="" host="" (or="" a="" closely="" related="" strain="" of="" the="" same="" species),="" or="" when="" transferred="" to="" another="" host="" by="" well="" established="" physiological="" means.="" section="" iii-e-4.="" those="" that="" consist="" entirely="" of="" dna="" from="" an="" eukaryotic="" host="" including="" its="" chloroplasts,="" mitochondria,="" or="" plasmids="" (but="" excluding="" viruses)="" when="" propagated="" only="" in="" that="" host="" (or="" a="" closely="" related="" strain="" of="" the="" same="" species).="" section="" iii-e-5.="" those="" that="" consist="" entirely="" of="" dna="" segments="" from="" different="" species="" that="" exchange="" dna="" by="" known="" physiological="" processes,="" though="" one="" or="" more="" of="" the="" segments="" may="" be="" a="" synthetic="" equivalent.="" a="" list="" of="" such="" exchangers="" will="" be="" prepared="" and="" periodically="" revised="" by="" the="" nih="" director="" with="" advice="" of="" the="" rac="" after="" appropriate="" notice="" and="" opportunity="" for="" public="" comment="" (see="" section="" iv-c-1-b-(1)-(c)).="" see="" appendices="" a-i="" through="" a-vi="" for="" a="" list="" of="" natural="" exchangers="" that="" are="" exempt="" from="" the="" nih="" guidelines.="" section="" iii-e-6.="" those="" that="" do="" not="" present="" a="" significant="" risk="" to="" health="" or="" the="" environment="" (see="" section="" iv-c-1-b-(1)-(c)),="" as="" determined="" by="" the="" nih="" director,="" with="" the="" advice="" of="" the="" rac,="" and="" following="" appropriate="" notice="" and="" opportunity="" for="" public="" comment.="" see="" appendix="" c="" for="" other="" classes="" of="" experiments="" which="" are="" exempt="" from="" the="" nih="" guidelines.''="" d.="" amendment="" to="" section="" iv,="" roles="" and="" responsibilities="" of="" the="" nih="" guidelines="" the="" amended="" version="" of="" section="" iv-c-1-b="" reads="" as="" follows:="" section="" iv-c-1-b.="" specific="" responsibilities="" [nih="" director]="" in="" carrying="" out="" the="" responsibilities="" set="" forth="" in="" this="" section,="" the="" nih="" director,="" or="" a="" designee="" shall="" weigh="" each="" proposed="" action="" through="" appropriate="" analysis="" and="" consultation="" to="" determine="" whether="" it="" complies="" with="" the="" nih="" guidelines="" and="" presents="" no="" significant="" risk="" to="" health="" or="" the="" environment.="" section="" iv-c-1-b-(1).="" major="" actions="" to="" execute="" major="" actions,="" the="" nih="" director="" shall="" seek="" the="" advice="" of="" the="" rac="" and="" provide="" an="" opportunity="" for="" public="" and="" federal="" agency="" comment.="" specifically,="" the="" notice="" of="" meeting="" and="" proposed="" actions="" to="" the="" nih="" guidelines="" shall="" be="" published="" in="" the="" federal="" register="" at="" least="" 15="" days="" before="" the="" rac="" meeting="" (not="" applicable="" for="" expedited="" review="" single="" patient="" human="" gene="" transfer="" experiments="" considered="" under="" appendix="" m-vi).="" the="" nih="" director's="" decision,="" at="" his/her="" discretion,="" may="" be="" published="" in="" the="" federal="" register="" for="" 15="" days="" of="" comment="" before="" final="" action="" is="" taken.="" the="" nih="" director's="" final="" decision,="" along="" with="" responses="" to="" public="" comments,="" shall="" be="" published="" in="" the="" federal="" register.="" the="" rac="" and="" institutional="" biosafety="" committee="" chairs="" shall="" be="" notified="" of="" the="" following="" decisions:="" section="" iv-c-1-b-(1)-(a).="" changing="" containment="" levels="" for="" types="" of="" experiments="" that="" are="" specified="" in="" the="" nih="" guidelines="" when="" a="" major="" action="" is="" involved;="" section="" iv-c-1-b-(1)-(b).="" assigning="" containment="" levels="" for="" types="" of="" experiments="" that="" are="" not="" explicitly="" considered="" in="" the="" nih="" guidelines="" when="" a="" major="" action="" is="" involved;="" section="" iv-c-1-b-(1)-(c).="" promulgating="" and="" amending="" a="" list="" of="" classes="" of="" recombinant="" dna="" molecules="" to="" be="" exempt="" from="" the="" nih="" guidelines="" because="" they="" consist="" entirely="" of="" dna="" segments="" from="" species="" that="" exchange="" dna="" by="" known="" physiological="" processes="" or="" otherwise="" do="" not="" present="" a="" significant="" risk="" to="" health="" or="" the="" environment;="" section="" iv-c-1-b-(1)-(d).="" permitting="" experiments="" specified="" by="" section="" iii-a;="" section="" iv-c-1-b-(1)-(e).="" certifying="" new="" host-vector="" systems="" with="" the="" exception="" of="" minor="" modifications="" of="" already="" certified="" systems="" (the="" standards="" and="" procedures="" for="" certification="" are="" described="" in="" appendix="" i-="" ii).="" minor="" modifications="" constitute="" (e.g.,="" those="" of="" minimal="" or="" no="" consequence="" to="" the="" properties="" relevant="" to="" containment);="" and="" section="" iv-c-1-b-(1)-(f).="" adopting="" other="" changes="" in="" the="" nih="" guidelines.="" section="" iv-c-1-b-(2).="" minor="" actions="" nih/orda="" shall="" carry="" out="" certain="" functions="" as="" delegated="" to="" it="" by="" the="" nih="" director="" (see="" section="" iv-c-3).="" minor="" actions="" (as="" determined="" by="" nih/orda="" in="" consultation="" with="" the="" rac="" chair="" and="" one="" or="" more="" rac="" members,="" as="" necessary)="" will="" be="" transmitted="" to="" the="" rac="" and="" institutional="" biosafety="" committee="" chairs:="" section="" iv-c-1-b-(2)-(a).="" reviewing="" and="" approving="" certain="" experiments="" involving="" the="" deliberate="" transfer="" of="" recombinant="" dna="" or="" dna="" or="" rna="" derived="" from="" recombinant="" dna="" into="" one="" or="" more="" human="" subjects="" that="" qualify="" for="" the="" accelerated="" review="" process="" (see="" section="" iii-b-2);="" section="" iv-c-1-b-(2)-(b).="" reviewing="" and="" approving="" minor="" changes="" to="" human="" gene="" transfer="" protocols="" under="" section="" iii-a-2="" and="" iii-b-2;="" section="" iv-c-1-b-(2)-(c).="" changing="" containment="" levels="" for="" experiments="" that="" are="" specified="" in="" section="" iii;="" section="" iv-c-1-b-(2)-(d).="" assigning="" containment="" levels="" for="" experiments="" not="" explicitly="" considered="" in="" the="" nih="" guidelines;="" and="" section="" iv-c-1-b-(2)-(e).="" revising="" the="" classification="" of="" etiologic="" agents="" for="" the="" purpose="" of="" these="" nih="" guidelines="" (see="" section="" v-a).="" section="" iv-c-1-b-(2)-(f).="" interpreting="" the="" nih="" guidelines="" for="" experiments="" to="" which="" the="" nih="" guidelines="" do="" not="" specifically="" assign="" containment="" levels;="" section="" iv-c-1-b-(2)-(g).="" setting="" containment="" under="" sections="" iii-c-="" 1-d="" and="" iii-c-2-b;="" section="" iv-c-1-b-(2)-(h).="" approving="" minor="" modifications="" of="" already="" certified="" host-vector="" systems="" (the="" standards="" and="" procedures="" for="" such="" modifications="" are="" described="" in="" appendix="" i-ii);="" section="" iv-c-1-b-(2)-(i).="" decertifying="" already="" certified="" host-="" vector="" systems;="" section="" iv-c-1-b-(2)-(j).="" adding="" new="" entries="" to="" the="" list="" of="" molecules="" toxic="" for="" vertebrates="" (see="" appendix="" f);="" and="" section="" iv-c-1-b-(2)-(k).="" determining="" appropriate="" containment="" conditions="" for="" experiments="" according="" to="" case="" precedents="" developed="" under="" section="" iv-c-1-b-(2)-(c).="" the="" amended="" version="" of="" section="" iv-c-2="" reads="" as="" follows:="" section="" iv-c-2.="" recombinant="" dna="" advisory="" committee="" (rac).="" the="" rac="" shall="" be="" responsible="" for="" advising="" the="" director,="" nih,="" on="" the="" actions="" listed="" in="" section="" iv-c-1-b-(1).="" the="" amended="" version="" of="" section="" iv-c-3="" reads="" as="" follows:="" section="" iv-c-3.="" office="" of="" recombinant="" dna="" activities="" (orda)="" orda="" shall="" serve="" as="" a="" focal="" point="" for="" information="" on="" recombinant="" dna="" activities="" and="" provide="" advice="" to="" all="" within="" and="" outside="" nih="" including="" institutions,="" biological="" safety="" officers,="" principal="" investigators,="" federal="" agencies,="" state="" and="" local="" governments,="" and="" institutions="" in="" the="" private="" sector.="" orda="" shall="" carry="" out="" such="" other="" functions="" as="" may="" be="" delegated="" to="" it="" by="" the="" nih="" director,="" including="" those="" authorities="" described="" in="" section="" iv-c-1-b-(2).="" orda's="" responsibilities="" include,="" but="" are="" not="" limited="" to="" the="" following:="" section="" iv-c-3-a.="" reviewing="" and="" approving="" experiments="" in="" conjunction="" with="" ad="" hoc="" experts="" involving="" the="" cloning="" of="" genes="" encoding="" for="" toxin="" molecules="" that="" are="" lethal="" for="" vertebrates="" at="" an="">50 
    100 nanograms per kilogram body weight in organisms other 
    than Escherichia coli K-12 (see Section III-B-1 and Appendices F-I and 
    F-II);
        Section IV-C-3-b. Reviewing and approving certain experiments 
    involving the deliberate transfer of recombinant DNA or DNA or RNA 
    derived from recombinant DNA into one or more human subjects, in 
    consultation with the RAC Chair and one or more RAC members, as 
    necessary, that qualify for the Accelerated Review process (see Section 
    III-B-2);
        Section IV-C-3-c. Reviewing and approving minor changes to human 
    gene transfer protocols approved under Sections III-A-2 and III-B-2, in 
    consultation with the RAC Chair and one or more RAC members, as 
    necessary;
        Section IV-C-3-d. Reviewing and approving the membership of an 
    institution's Institutional Biosafety Committee, and where it finds the 
    Institutional Biosafety Committee meets the requirements set forth in 
    Section IV-B-2 will give its approval to the Institutional Biosafety 
    Committee membership;
        Section IV-C-3-e. Publishing in the Federal Register:
        Section IV-C-3-e-(1). Announcements of RAC meetings and agendas at 
    least 15 days in advance (Note--If the agenda for a RAC meeting is 
    modified, ORDA shall make the revised agenda available to anyone upon 
    request at least 72 hours in advance of the meeting);
        Section IV-C-3-e-(2). Proposed Major Actions to the NIH Guidelines 
    (see Section IV-C-1-b-(1)) at least 15 days prior to the RAC meeting;
        Section IV-C-3-f. Serve as the focal point for data management of 
    NIH-approved human gene transfer protocols approved under Sections III-
    A-2 and III-B-2 and registered with NIH/ORDA as required under Section 
    III-C-7;
        Section IV-C-3-g. Serve as the executive secretary of the RAC; and
        Section IV-C-3-h. Maintain a list of Major and Minor Actions 
    approved under Section III-A-2 and III-B-3 and a list of experiments 
    registered with NIH/ORDA as described in Section III-C-7.
    
    E. Amendment and Addition to Section V, Footnotes and References of 
    Sections I-IV of the NIH Guidelines
    
        The amended version of Section V-U reads as follows:
        Section V-U. Human studies in which the induction or enhancement of 
    an immune response to a vector-encoded microbial immunogen is the major 
    goal, such an immune response has been demonstrated in model systems, 
    and the persistence of the vector-encoded immunogen is not expected, 
    are not covered under Sections III-A-2, III-B-2, or III-B-3. Such 
    studies may be initiated without RAC review and NIH approval if 
    approved by another Federal agency.''
        The following new footnote, V-W is added to Section V:
        Section V-W. In accordance with accepted scientific and regulatory 
    practices of the discipline of plant pathology, an exotic plant 
    pathogen (e.g., virus, bacteria, or fungus) is one that is unknown to 
    occur within the U.S. (see Section V-R). Determination of whether a 
    pathogen has a potential for serious detrimental impact on managed 
    (agricultural, forest, grassland) or natural ecosystems should be made 
    by the Principal Investigator and the Institutional Biosafety 
    Committee, in consultation with scientists knowledgeable of plant 
    diseases, crops, and ecosystems in the geographic area of the research.
    
    F. Addition to Appendix C-I, Recombinant DNA in Tissue Culture, of the 
    NIH Guidelines
    
        The amended version of Appendix C-I reads as follows:
        Appendix C-I. Recombinant DNA in Tissue Culture
        Recombinant DNA molecules containing less than one-half of any 
    eukaryotic viral genome (all viruses from a single family (see Appendix 
    C-VI-D) being considered identical (see Appendix C-VI-E), that are 
    propagated and maintained in cells in tissue culture are exempt from 
    these NIH Guidelines with the exceptions listed in Appendix C-I-A.
    Appendix C-I-A. Exceptions
        The following categories are not exempt from the NIH Guidelines: 
    (i) Experiments described in Section III-A which require specific RAC 
    review and NIH and Institutional Biosafety Committee approval before 
    initiation, (ii) experiments described in Section III-B which require 
    NIH/ORDA and Institutional Biosafety Committee approval before 
    initiation, (iii) experiments involving DNA from Class 3, 4, or 5 
    organisms (see Appendix C-VI-A) or cells known to be infected with 
    these agents, (iv) experiments involving the deliberate introduction of 
    genes coding for the biosynthesis of molecules that are toxic for 
    vertebrates (see Appendix F), and (v) whole plants regenerated from 
    plant cells and tissue cultures are covered by the exemption provided 
    they remain axenic cultures even though they differentiate into 
    embryonic tissue and regenerate into plantlets.
    
    G. Addition to Appendix G, Physical Containment, of the NIH Guidelines
    
        Appendix G through G-I is amended to read as follows:
        Appendix G specifies physical containment for standard laboratory 
    experiments and defines Biosafety Level 1 through Biosafety Level 4. 
    For large scale (over 10 liters) research or production, Appendix K 
    supersedes Appendix G. Appendix K defines Good Large Scale Practice 
    through Biosafety Level 3--Large Scale. For certain work with plants, 
    Appendix P supersedes Appendix G. Appendix P defines Biosafety Levels 1 
    through 4--Plants. For certain work with animals, Appendix Q supersedes 
    Appendix G. Appendix Q defines Biosafety Levels 1 through 4--Animals.
    Appendix G-I. Standard Practices and Training
        The first principle of containment is strict adherence to good 
    microbiological practices (see Appendices G-III-A through G-III-J). 
    Consequently, all personnel directly or indirectly involved in 
    experiments using recombinant DNA shall receive adequate instruction 
    (see Sections IV-B-1-e and IV-B-4-d). At a minimum, these instructions 
    include training in aseptic techniques and in the biology of the 
    organisms used in the experiments so that the potential biohazards can 
    be understood and appreciated.
        Any research group working with agents that are known or potential 
    biohazards shall have an emergency plan that describes the procedures 
    to be followed if an accident contaminates personnel or the 
    environment. The Principal Investigator shall ensure that everyone in 
    the laboratory is familiar with both the potential hazards of the work 
    and the emergency plan (see Sections IV-B-4-d and IV-B-4-e). If a 
    research group is working with a known pathogen for which there is an 
    effective vaccine, the vaccine should be made available to all workers. 
    Serological monitoring, when clearly appropriate, will be provided (see 
    Section IV-B-1-f).
        The Laboratory Safety Monograph (see Appendix G-III-O) and 
    Biosafety in Microbiological and Biomedical Laboratories (see Appendix 
    G-III-B) describe practices, equipment, and facilities in detail.
    
    H. Addition of Appendix P, Physical and Biological Containment for 
    Recombinant DNA Research Involving Plants, to the NIH Guidelines
    
        The following new appendix, Appendix P, reads as follows:
        Appendix P specifies physical and biological containment conditions 
    and practices suitable to the greenhouse conduct of experiments 
    involving recombinant DNA-containing plants, plant-associated 
    microorganisms, and small animals. All provisions of the NIH Guidelines 
    apply to plant research activities with the following modifications:
        Appendix P shall supersede Appendix G when the research plants are 
    of a size, number, or have growth requirements that preclude the use of 
    containment conditions described in Appendix G. The plants covered in 
    Appendix P include but are not limited to mosses, liverworts, 
    macroscopic algae, and vascular plants including terrestrial crops, 
    forest, and ornamental species.
        Plant-associated microorganisms include viroids, virusoids, 
    viruses, bacteria, fungi, protozoans, certain small algae, and 
    microorganisms that have a benign or beneficial association with 
    plants, such as certain Rhizobium species and microorganisms known to 
    cause plant diseases. The appendix applies to microorganisms which are 
    being modified with the objective of fostering an association with 
    plants.
        Plant-associated small animals include those arthropods that: (i) 
    Are in obligate association with plants, (ii) are plant pests, (iii) 
    are plant pollinators, or (iv) transmit plant disease agents, as well 
    as other small animals such as nematodes for which tests of biological 
    properties necessitate the use of plants. Microorganisms associated 
    with such small animals (e.g., pathogens or symbionts) are included.
        The Institutional Biosafety Committee shall include at least one 
    individual with expertise in plant, plant pathogen, or plant pest 
    containment principles when experiments utilizing Appendix P require 
    prior approval by the Institutional Biosafety Committee.
    Appendix P-I. General Plant Biosafety Levels
        Appendix P-I-A. The principal purpose of plant containment is to 
    avoid the unintentional transmission of a recombinant DNA-containing 
    plant genome, including nuclear or organelle hereditary material or 
    release of recombinant DNA-derived organisms associated with plants.
        Appendix P-I-B. The containment principles are based on the 
    recognition that the organisms that are used pose no health threat to 
    humans or higher animals (unless deliberately modified for that 
    purpose), and that the containment conditions minimize the possibility 
    of an unanticipated deleterious effect on organisms and ecosystems 
    outside of the experimental facility, e.g., the inadvertent spread of a 
    serious pathogen from a greenhouse to a local agricultural crop or the 
    unintentional introduction and establishment of an organism in a new 
    ecosystem.
        Appendix P-I-C. Four biosafety levels, referred to as Biosafety 
    Level (BL) 1--Plants (P), BL2-P, BL3-P, and BL4-P, are established in 
    Section II. The selection of containment levels required for research 
    involving recombinant DNA molecules in plants or associated with plants 
    is specified in Section III. These biosafety levels are described in 
    Appendix P-II. This appendix describes greenhouse practices and special 
    greenhouse facilities for physical containment.
        Appendix P-I-D. BL1-P through BL4-P are designed to provide 
    differential levels of biosafety for plants in the absence or presence 
    of other experimental organisms that contain recombinant DNA. These 
    biosafety levels, in conjunction with biological containment conditions 
    described in Appendix P-III, provide flexible approaches to ensure the 
    safe conduct of research.
        Appendix P-I-E. For experiments in which plants are grown at the 
    BL1 through BL4 laboratory settings, containment practices shall be 
    followed as described in Appendix G. These containment practices 
    include the use of plant tissue culture rooms, growth chambers within 
    laboratory facilities, or experiments performed on open benches. 
    Additional biological containment practices should be added by the 
    Greenhouse Director or Institutional Biosafety Committee as necessary 
    (see Appendix P-III), if botanical reproductive structures are produced 
    that have the potential of being released.
        Appendix P-II. Physical Containment Levels
        Appendix P-II-A. Biosafety Level 1--Plants (BL1-P)
        Appendix P-II-A-1. Standard Practices (BL1-P)
        Appendix P-II-A-1-a. Greenhouse Access (BL1-P)
        Appendix P-II-A-1-a-(1). Access to the greenhouse shall be limited 
    or restricted, at the discretion of the Greenhouse Director, when 
    experiments are in progress.
        Appendix P-II-A-1-a-(2). Prior to entering the greenhouse, 
    personnel shall be required to read and follow instructions on BL1-P 
    greenhouse practices and procedures. All procedures shall be performed 
    in accordance with accepted greenhouse practices that are appropriate 
    to the experimental organism.
    Appendix P-II-A-1-b. Records (BL1-P)
        Appendix P-II-A-1-b-(1). A record shall be kept of experiments 
    currently in progress in the greenhouse facility.
    Appendix P-II-A-1-c. Decontamination and Inactivation (BL1-P)
        Appendix P-II-A-1-c-(1). Experimental organisms shall be rendered 
    biologically inactive by appropriate methods before disposal outside of 
    the greenhouse facility.
    Appendix P-II-A-1-d. Control of Undesired Species and Motile 
    Macroorganisms (BL1-P)
        Appendix P-II-A-1-d-(1). A program shall be implemented to control 
    undesired species (e.g., weed, rodent, or arthropod pests and 
    pathogens), by methods appropriate to the organisms and in accordance 
    with applicable state and Federal laws.
        Appendix P-II-A-1-d-(2). Arthropods and other motile macroorganisms 
    shall be housed in appropriate cages. If macroorganisms (e.g., flying 
    arthropods or nematodes) are released within the greenhouse, 
    precautions shall be taken to minimize escape from the greenhouse 
    facility.
    Appendix P-II-A-1-e. Concurrent Experiments Conducted in the Greenhouse 
    (BL1-P)
        Appendix P-II-A-1-e-(1). Experiments involving other organisms that 
    require a containment level lower than BL1-P may be conducted in the 
    greenhouse concurrently with experiments that require BL1-P 
    containment, provided that all work is conducted in accordance with 
    BL1-P greenhouse practices.
    Appendix P-II-A-2. Facilities (BL1-P)
    Appendix P-II-A-2-a. Definitions (BL1-P)
        Appendix P-II-A-2-a-(1). The term `greenhouse' refers to a 
    structure with walls, a roof, and a floor designed and used principally 
    for growing plants in a controlled and protected environment. The walls 
    and roof are usually constructed of transparent or translucent material 
    to allow passage of sunlight for plant growth.
        Appendix P-II-A-2-a-(2). The term `greenhouse facility' includes 
    the actual greenhouse rooms or compartments for growing plants, 
    including all immediately contiguous hallways and head-house areas, and 
    is considered part of the confinement area.
    Appendix P-II-A-2-b. Greenhouse Design (BL1-P)
        Appendix P-II-A-2-b-(1). The greenhouse floor may be composed of 
    gravel or other porous material. At a minimum, impervious (e.g., 
    concrete) walkways are recommended.
        Appendix P-II-A-2-b-(2). Windows and other openings in the walls 
    and roof of the greenhouse facility may be open for ventilation as 
    needed for proper operation and do not require any special barrier to 
    contain or exclude pollen, microorganisms, or small flying animals 
    (e.g., arthropods and birds); however, screens are recommended.
    Appendix P-II-B. Biosafety Level 2--Plants (BL2-P)
    Appendix P-II-B-1. Standard Practices (BL2-P)
    Appendix P-II-B-1-a. Greenhouse Access (BL2-P)
        Appendix P-II-B-1-a-(1). Access to the greenhouse shall be limited 
    or restricted, at the discretion of the Greenhouse Director, to 
    individuals directly involved with the experiments when they are in 
    progress.
        Appendix P-II-B-1-a-(2). Personnel shall be required to read and 
    follow instructions on BL2-P practices and procedures. All procedures 
    shall be conducted in accordance with accepted greenhouse practices 
    that are appropriate to the experimental organisms.
    Appendix P-II-B-1-b. Records (BL2-P)
        Appendix P-II-B-1-b-(1). A record shall be kept of experimental 
    plants, microorganisms, or small animals that are brought into or 
    removed from the greenhouse facility.
        Appendix P-II-B-1-b-(2). A record shall be kept of experiments 
    currently in progress in the greenhouse facility.
        Appendix P-II-B-1-b-(3). The Principal Investigator shall report 
    any greenhouse accident involving the inadvertent release or spill of 
    microorganisms to the Greenhouse Director, Institutional Biosafety 
    Committee, NIH/ORDA and other appropriate authorities immediately (if 
    applicable). Reports to the NIH/ORDA shall be sent to the Office of 
    Recombinant DNA Activities, National Institutes of Health, Building 31, 
    Room 4B11, Bethesda, Maryland 20892, (301) 496-9838. Documentation of 
    any such accident shall be prepared and maintained.
    Appendix P-II-B-1-c. Decontamination and Inactivation (BL2-P)
        Appendix P-II-B-1-c-(1). Experimental organisms shall be rendered 
    biologically inactive by appropriate methods before disposal outside of 
    the greenhouse facility.
        Appendix P-II-B-1-c-(2). Decontamination of run-off water is not 
    necessarily required. If part of the greenhouse is composed of gravel 
    or similar material, appropriate treatments should be made periodically 
    to eliminate, or render inactive, any organisms potentially entrapped 
    by the gravel.
    Appendix P-II-B-1-d. Control of Undesired Species and Motile 
    Macroorganisms (BL2-P)
        Appendix P-II-B-1-d-(1). A program shall be implemented to control 
    undesired species (e.g., weed, rodent, or arthropod pests and 
    pathogens) by methods appropriate to the organisms and in accordance 
    with applicable state and Federal laws.
        Appendix P-II-B-1-d-(2). Arthropods and other motile macroorganisms 
    shall be housed in appropriate cages. If macroorganisms (e.g., flying 
    arthropods or nematodes) are released within the greenhouse, 
    precautions shall be taken to minimize escape from the greenhouse 
    facility.
    Appendix P-II-B-1-e. Concurrent Experiments Conducted in the Greenhouse 
    (BL2-P)
        Appendix P-II-B-1-e-(1). Experiments involving other organisms that 
    require a containment level lower than BL2-P may be conducted in the 
    greenhouse concurrently with experiments that require BL2-P containment 
    provided that all work is conducted in accordance with BL2-P greenhouse 
    practices.
    Appendix P-II-B-1-f. Signs (BL2-P)
        Appendix P-II-B-1-f-(1). A sign shall be posted indicating that a 
    restricted experiment is in progress. The sign shall indicate the 
    following: (i) the name of the responsible individual, (ii) The plants 
    in use, and (iii) any special requirements for using the area.
        Appendix P-II-B-1-f-(2). If organisms are used that have a 
    recognized potential for causing serious detrimental impacts on managed 
    or natural ecosystems, their presence shall be indicated on a sign 
    posted on the greenhouse access doors.
        Appendix P-II-B-1-f-(3). If there is a risk to human health, a sign 
    shall be posted incorporating the universal biosafety symbol.
    Appendix P-II-B-1-g. Transfer of Materials (BL2-P)
        Appendix P-II-B-1-g-(1). Materials containing experimental 
    microorganisms, which are brought into or removed from the greenhouse 
    facility in a viable or intact state, shall be transferred in a closed 
    non-breakable container.
    Appendix P-II-B-1-h. Greenhouse Practices Manual (BL2-P)
        Appendix P-II-B-1-h-(1). A greenhouse practices manual shall be 
    prepared or adopted. This manual shall: (i) Advise personnel of the 
    potential consequences if such practices are not followed, and (ii) 
    outline contingency plans to be implemented in the event of the 
    unintentional release of organisms.
    Appendix P-II-B-2. Facilities (BL2-P)
    Appendix P-II-B-2-a. Definitions (BL2-P)
        Appendix P-II-B-2-a-(1). The term `greenhouse' refers to a 
    structure with walls, a roof, and a floor designed and used principally 
    for growing plants in a controlled and protected environment. The walls 
    and roof are usually constructed of transparent or translucent material 
    to allow passage of sunlight for plant growth.
        Appendix P-II-B-2-a-(2). The term `greenhouse facility' includes 
    the actual greenhouse rooms or compartments for growing plants, 
    including all immediately contiguous hallways and head-house areas and 
    is considered part of the confinement area.
    Appendix P-II-B-2-b. Greenhouse Design (BL2-P)
        Appendix P-II-B-2-b-(1). A greenhouse floor composed of an 
    impervious material. Concrete is recommended, but gravel or other 
    porous material under benches is acceptable unless propagules of 
    experimental organisms are readily disseminated through soil. Soil beds 
    are acceptable unless propagules of experimental organisms are readily 
    disseminated through soil.
        Appendix P-II-B-2-b-(2). Windows and other openings in the walls 
    and roof of the greenhouse facility may be open for ventilation as 
    needed for proper operation and do not require any special barrier to 
    exclude pollen or microorganisms; however, screens are required to 
    exclude small flying animals (e.g., arthropods and birds).
    Appendix P-II-B-2-c. Autoclaves (BL2-P)
        Appendix P-II-B-2-c-(1). An autoclave shall be available for the 
    treatment of contaminated greenhouse materials.
    Appendix P-II-B-2-d. Supply and Exhaust Air Ventilation Systems (BL2-P)
        Appendix P-II-B-2-d-(1). If intake fans are used, measures shall be 
    taken to minimize the ingress of arthropods. Louvers or fans shall be 
    constructed such that they can only be opened when the fan is in 
    operation.
    Appendix P-II-B-2-e. Other (BL2-P)
        Appendix P-II-B-2-e-(1). BL2-P greenhouse containment requirements 
    may be satisfied by using a growth chamber or growth room within a 
    building provided that the external physical structure limits access 
    and escape of microorganisms and macroorganisms in a manner that 
    satisfies the intent of the foregoing clauses.
    Appendix P-II-C. Biosafety Level 3--Plants (BL3-P)
    Appendix P-II-C-1. Standard Practices (BL3-P)
    Appendix P-II-C-1-a. Greenhouse Access (BL3-P)
        Appendix P-II-C-1-a-(1). Authorized entry into the greenhouse shall 
    be restricted to individuals who are required for program or support 
    purposes. The Greenhouse Director shall be responsible for assessing 
    each circumstance and determining those individuals who are authorized 
    to enter the greenhouse facility.
        Appendix P-II-C-1-a-(2). Prior to entering the greenhouse, 
    personnel shall be required to read and follow instructions on BL3-P 
    practices and procedures. All procedures shall be conducted in 
    accordance with accepted greenhouse practices that are appropriate to 
    the experimental organisms.
    Appendix P-II-C-1-b. Records (BL3-P)
        Appendix P-II-C-1-b-(1). A record shall be kept of experimental 
    plants, microorganisms, or small animals that are brought into or 
    removed from the greenhouse facility.
        Appendix P-II-C-1-b-(2). A record shall be kept of experiments 
    currently in progress in the greenhouse facility.
        Appendix P-II-C-1-b-(3). The Principal Investigator shall report 
    any greenhouse accident involving the inadvertent release or spill of 
    microorganisms to the Biological Safety Officer, Greenhouse Director, 
    Institutional Biosafety Committee, NIH/ORDA, and other appropriate 
    authorities immediately (if applicable).
        Reports to the NIH/ORDA shall be sent to the Office of Recombinant 
    DNA Activities, National Institutes of Health, Building 31, Room 4B11, 
    Bethesda, Maryland 20892, (301) 496-9838. Documentation of any such 
    accident shall be prepared and maintained.
    Appendix P-II-C-1-c. Decontamination and Inactivation (BL3-P)
        Appendix P-II-C-1-c-(1). All experimental materials shall be 
    sterilized in an autoclave or rendered biologically inactive by 
    appropriate methods before disposal, except those that are to remain in 
    a viable or intact state for experimental purposes; including water 
    that comes in contact with experimental microorganisms or with material 
    exposed to such microorganisms, and contaminated equipment and 
    supplies.
    Appendix P-II-C-1-d. Control of Undesired Species and Motile 
    Macroorganisms (BL3-P)
        Appendix P-II-C-1-d-(1). A program shall be implemented to control 
    undesired species (e.g., weed, rodent, or arthropod pests and 
    pathogens) by methods appropriate to the organisms and in accordance 
    with applicable state and Federal laws.
        Appendix P-II-C-1-d-(2). Arthropods and other motile macroorganisms 
    shall be housed in appropriate cages. When appropriate to the organism, 
    experiments shall be conducted within cages designed to contain the 
    motile organisms.
    Appendix P-II-C-1-e. Concurrent Experiments Conducted in the Greenhouse 
    (BL3-P)
        Appendix P-II-C-1-e-(1). Experiments involving organisms that 
    require a containment level lower than BL3-P may be conducted in the 
    greenhouse concurrently with experiments that require BL3-P containment 
    provided that all work is conducted in accordance with BL3-P greenhouse 
    practices.
    Appendix P-II-C-1-f. Signs (BL3-P)
        Appendix P-II-C-1-f-(1). A sign shall be posted indicating that a 
    restricted experiment is in progress. The sign shall indicate the 
    following: (i) The name of the responsible individual, (ii) the plants 
    in use, and (iii) any special requirements for using the area.
        Appendix P-II-C-1-f-(2). If organisms are used that have a 
    recognized potential for causing serious detrimental impacts on managed 
    or natural ecosystems, their presence should be indicated on a sign 
    posted on the greenhouse access doors.
        Appendix P-II-C-1-f-(3). If there is a risk to human health, a sign 
    shall be posted incorporating the universal biosafety symbol.
    Appendix P-II-C-1-g. Transfer of Materials (BL3-P)
        Appendix P-II-C-1-g-(1). Experimental materials that are brought 
    into or removed from the greenhouse facility in a viable or intact 
    state shall be transferred to a non-breakable sealed secondary 
    container. At the time of transfer, if the same plant species, host, or 
    vector are present within the effective dissemination distance of 
    propagules of the experimental organism, the surface of the secondary 
    container shall be decontaminated. Decontamination may be accomplished 
    by passage through a chemical disinfectant or fumigation chamber or by 
    an alternative procedure that has demonstrated effective inactivation 
    of the experimental organism.
    Appendix P-II-C-1-h. Greenhouse Practices Manual (BL3-P)
        Appendix P-II-C-1-h-(1). A greenhouse practices manual shall be 
    prepared or adopted. This manual shall: (i) Advise personnel of the 
    potential consequences if such practices are not followed, and (ii) 
    outline contingency plans to be implemented in the event of the 
    unintentional release of organisms with recognized potential for 
    serious detrimental impact.
    Appendix P-II-C-1-i. Protective Clothing (BL3-P)
        Appendix P-II-C-1-i-(1). Disposable clothing (e.g., solid front or 
    wrap-around gowns, scrub suits, or other appropriate clothing) shall be 
    worn in the greenhouse if deemed necessary by the Greenhouse Director 
    because of potential dissemination of the experimental microorganisms.
        Appendix P-II-C-1-i-(2). Protective clothing shall be removed 
    before exiting the greenhouse and decontaminated prior to laundering or 
    disposal.
    Appendix P-II-C-1-j. Other (BL3-P)
        Appendix P-II-C-1-j-(1). Personnel are required to thoroughly wash 
    their hands upon exiting the greenhouse.
        Appendix P-II-C-1-j-(2). All procedures shall be performed 
    carefully to minimize the creation of aerosols and excessive splashing 
    of potting material/soil during watering, transplanting, and all 
    experimental manipulations.
    Appendix P-II-C-2. Facilities (BL3-P)
    Appendix P-II-C-2-a. Definitions (BL3-P)
        Appendix P-II-C-2-a-(1). The term 'greenhouse' refers to a 
    structure with walls, roof, and floor designed and used principally for 
    growing plants in a controlled and protected environment. The walls and 
    roof are usually constructed of transparent or translucent material to 
    allow passage of sunlight for plant growth.
        Appendix P-II-C-2-a-(2). The term 'greenhouse facility' includes 
    the actual greenhouse rooms or compartments for growing plants, 
    including all immediately contiguous hallways and head-house areas, and 
    is considered part of the confinement area. The need to maintain 
    negative pressure should be considered when constructing or renovating 
    the greenhouse.
    Appendix P-II-C-2-b. Greenhouse Design (BL3-P)
        Appendix P-II-C-2-b-(1). The greenhouse floor shall be composed of 
    concrete or other impervious material with provision for collection and 
    decontamination of liquid run-off.
        Appendix P-II-C-2-b-(2). Windows shall be closed and sealed. All 
    glazing shall be resistant to breakage (e.g., double-pane tempered 
    glass or equivalent).
        Appendix P-II-C-2-b-(3). The greenhouse shall be a closed self-
    contained structure with a continuous covering that is separated from 
    areas that are open to unrestricted traffic flow. The minimum 
    requirement for greenhouse entry shall be passage through two sets of 
    self-closing locking doors.
        Appendix P-II-C-2-b-(4). The greenhouse facility shall be 
    surrounded by a security fence or protected by equivalent security 
    measures.
        Appendix P-II-C-2-b-(5). Internal walls, ceilings, and floors shall 
    be resistant to penetration by liquids and chemicals to facilitate 
    cleaning and decontamination of the area. All penetrations into these 
    structures and surfaces (e.g., plumbing and utilities) shall be sealed.
        Appendix P-II-C-2-b-(6). Bench tops and other work surfaces should 
    have seamless surfaces that are impervious to water and resistant to 
    acids, alkalis, organic solvents, and moderate heat.
        Appendix P-II-C-2-b-(7). The greenhouse contains a foot, elbow, or 
    automatically operated sink, which is located near the exit door for 
    hand washing.
    Appendix P-II-C-2-c. Autoclaves (BL3-P)
        Appendix P-II-C-2-c-(1). An autoclave shall be available for 
    decontaminating materials within the greenhouse facility. A double-door 
    autoclave is recommended (not required) for the decontamination of 
    materials passing out of the greenhouse facility.
    Appendix P-II-C-2-d. Supply and Exhaust Air Ventilation Systems (BL3-P)
        Appendix P-II-C-2-d-(1). An individual supply and exhaust air 
    ventilation system shall be provided. The system maintains pressure 
    differentials and directional airflow, as required, to assure inward 
    (or zero) airflow from areas outside of the greenhouse.
        Appendix P-II-C-2-d-(2). The exhaust air from the greenhouse 
    facility shall be filtered through high efficiency particulate air-HEPA 
    filters and discharged to the outside. The filter chambers shall be 
    designed to allow in situ decontamination before filters are removed 
    and to facilitate certification testing after they are replaced. Air 
    filters shall be 80-85% average efficiency by the American Society of 
    Heating, Refrigerating, and Air Conditioning Engineers (ASHRAE) 
    Standard 52- 68 test method using atmosphere dust. Air supply fans 
    shall be equipped with a back-flow damper that closes when the air 
    supply fan is off. Alternatively, a HEPA filter may be used on the air 
    supply system instead of the filters and damper. The supply and exhaust 
    airflow shall be interlocked to assure inward (or zero) airflow at all 
    times.
    Appendix P-II-C-2-e. Other (BL3-P)
        Appendix P-II-C-2-e-(1). BL3-P greenhouse containment requirements 
    may be satisfied using a growth chamber or growth room within a 
    building provided that the location, access, airflow patterns, and 
    provisions for decontamination of experimental materials and supplies 
    meet the intent of the foregoing clauses.
        Appendix P-II-C-2-e-(2). Vacuum lines shall be protected with high 
    efficiency particulate air/HEPA or equivalent filters and liquid 
    disinfectant traps.
    Appendix P-II-D. Biosafety Level 4--Plants (BL4-P)
    Appendix P-II-D-1. Standard Practices (BL4-P)
    Appendix P-II-D-1-a. Greenhouse Access (BL4-P)
        Appendix P-II-D-1-a-(1). Authorized entry into the greenhouse shall 
    be restricted to individuals who are required for program or support 
    purposes. The Greenhouse Director shall be responsible for assessing 
    each circumstance and determining those individuals who are authorized 
    to enter the greenhouse facility or work in the greenhouse during 
    experiments.
        Appendix P-II-D-1-a-(2). Access shall be managed by the Greenhouse 
    Director, Biological Safety Officer, or other individual responsible 
    for physical security of the greenhouse facility; and access limited by 
    means of secure, locked doors.
        Appendix P-II-D-1-a-(3). Prior to entering, individuals shall be 
    advised of the potential environmental hazards and instructed on 
    appropriate safeguards for ensuring environmental safety. Individuals 
    authorized to enter the greenhouse facility shall comply with the 
    instructions and all other applicable entry/exit procedures.
        Appendix P-II-D-1-a-(4). Personnel shall enter and exit the 
    greenhouse facility only through the clothing change and shower rooms 
    and shall shower each time they exit the greenhouse facility. Personnel 
    shall use the airlocks to enter or exit the laboratory only in an 
    emergency. In the event of an emergency, every reasonable effort should 
    be made to prevent the possible transport of viable propagules from 
    containment.
        Appendix P-II-D-1-a-(5). Prior to entering the greenhouse, 
    personnel shall be required to read and follow instructions on BL4-P 
    practices and procedures.
    Appendix P-II-D-1-b. Records (BL4-P)
        Appendix P-II-D-1-b-(1). A record shall be kept of all experimental 
    materials brought into or removed from the greenhouse.
        Appendix P-II-D-1-b-(2). A record shall be kept of experiments 
    currently in progress in the greenhouse facility.
        Appendix P-II-D-1-b-(3). A record shall be kept of all personnel 
    entering and exiting the greenhouse facility, including the date and 
    time of each entry.
        Appendix P-II-D-1-b-(4). The Principal Investigator shall report 
    any greenhouse accident involving the inadvertent release or spill of 
    microorganisms to the Biological Safety Officer, Greenhouse Director, 
    Institutional Biosafety Committee, NIH/ORDA, and other appropriate 
    authorities immediately (if applicable). Reports to the NIH/ORDA shall 
    be sent to the Office of Recombinant DNA Activities, National 
    Institutes of Health, Building 31, Room 4B11, Bethesda, Maryland 20892, 
    (301) 496-9838. Documentation of any such accident shall be prepared 
    and maintained.
    Appendix P-II-D-1-c. Decontamination and Inactivation (BL4-P)
        Appendix P-II-D-1-c-(1). All materials, except for those that are 
    to remain in a viable or intact state for experimental purposes, shall 
    be autoclaved prior to removal from the maximum containment greenhouse. 
    Equipment or material that could be damaged by high temperatures or 
    steam shall be decontaminated by alternative methods (e.g., gas or 
    vapor sterilization) in an airlock or chamber designed for this 
    purpose.
        Appendix P-II-D-1-c-(2). Water that comes in contact with 
    experimental microorganisms or with material exposed to such 
    microorganisms (e.g., run-off from watering plants) shall be collected 
    and decontaminated before disposal.
        Appendix P-II-D-1-c-(3). Standard microbiological procedures shall 
    be followed for decontamination of equipment and materials. Spray or 
    liquid waste or rinse water from containers used to apply the 
    experimental microorganisms shall be decontaminated before disposal.
    Appendix P-II-D-1-d. Control of Undesired Species and Motile 
    Macroorganisms (BL4-P)
        Appendix P-II-D-1-d-(1). A chemical control program shall be 
    implemented to eliminate undesired pests and pathogens in accordance 
    with applicable state and Federal laws.
        Appendix P-II-D-1-d-(2). Arthropods and other motile macroorganisms 
    used in conjunction with experiments requiring BL4-P level physical 
    containment shall be housed in appropriate cages. When appropriate to 
    the organism, experiments shall be conducted within cages designed to 
    contain the motile organisms.
    Appendix P-II-D-1-e. Concurrent Experiments Conducted in the Greenhouse 
    (BL4-P)
        Appendix P-II-D-1-e-(1). Experiments involving organisms that 
    require a containment level lower than BL4-P may be conducted in the 
    greenhouse concurrently with experiments that require BL4-P containment 
    provided that all work is conducted in accordance with BL4-P greenhouse 
    practices. When the experimental microorganisms in use require a 
    containment level lower than BL4-P, greenhouse practices reflect the 
    level of containment required by the highest containment level 
    microorganisms being tested.
    Appendix P-II-D-1-f. Signs (BL4-P)
        Appendix P-II-D-1-f-(1). A sign shall be posted indicating that a 
    restricted experiment is in progress. The sign shall indicate the 
    following: (i) The name of the responsible individual, (ii) the plants 
    in use, and (iii) any special requirements for using the area.
        Appendix P-II-D-1-f-(2). If organisms are used that have a 
    recognized potential for causing serious detrimental impacts on managed 
    or natural ecosystems, their presence shall be indicated by a sign 
    posted on the greenhouse access doors.
        Appendix P-II-D-1-f-(3). If there is a risk to human health, a sign 
    shall be posted incorporating the universal biosafety symbol.
    Appendix P-II-D-1-g. Transfer of Materials (BL4-P)
        Appendix P-II-D-1-g-(1). Experimental materials that are brought 
    into or removed from the greenhouse in a viable or intact state shall 
    be transferred to a non-breakable, sealed, primary container then 
    enclosed in a non-breakable, sealed secondary container. These 
    containers shall be removed from the greenhouse facility through a 
    chemical disinfectant, fumigation chamber, or an airlock designed for 
    this purpose.
        Appendix P-II-D-g-(2). Supplies and materials shall be brought into 
    the greenhouse facility through a double-door autoclave, fumigation 
    chamber, or airlock that is appropriately decontaminated between each 
    use. After securing the outer doors, personnel within the greenhouse 
    facility shall retrieve the materials by opening the interior door of 
    the autoclave, fumigation chamber, or airlock. These doors shall be 
    secured after the materials are brought into the greenhouse facility.
    Appendix P-II-D-1-h. Greenhouse Practices Manual (BL4-P)
        Appendix P-II-D-1-h-(1). A greenhouse practices manual shall be 
    prepared or adopted. This manual shall include contingency plans to be 
    implemented in the event of the unintentional release of experimental 
    organisms.
    Appendix P-II-D-1-i. Protective Clothing (BL4-P)
        Appendix P-II-D-1-i-(1). Street clothing shall be removed in the 
    outer clothing change room. Complete laboratory clothing (may be 
    disposable) including undergarments, pants, and shirts, jump suits, 
    shoes, and hats shall be provided and worn by all personnel entering 
    the greenhouse facility.
        Appendix P-II-D-1-i-(2). Personnel shall remove laboratory clothing 
    when exiting the greenhouse facility and before entering the shower 
    area. This clothing shall be stored in a locker or hamper in the inner 
    change room.
        Appendix P-II-D-1-i-(3). All laboratory clothing shall be 
    autoclaved before laundering.
    Appendix P-II-D-2. Facilities (BL4-P)
    Appendix P-II-D-2-a. Greenhouse Design (BL4-P)
        Appendix P-II-D-2-a-(1). The maximum containment greenhouse 
    facility shall consist of a separate building or a clearly demarcated 
    and isolated area within a building. The need to maintain negative 
    pressure should be considered when constructing or renovating the 
    greenhouse facility.
        Appendix P-II-D-2-a-(2). Outer and inner change rooms, separated by 
    a shower, shall be provided for personnel entering and exiting the 
    greenhouse facility.
        Appendix P-II-D-2-a-(3). Windows shall be closed and sealed. All 
    glazing shall be resistant to breakage (e.g., double-pane tempered 
    glass or equivalent).
        Appendix P-II-D-2-a-(4). Access doors to the greenhouse shall be 
    self-closing and locking.
        Appendix P-II-D-2-a-(5). The greenhouse facility shall be 
    surrounded by a security fence or protected by equivalent security 
    measures.
        Appendix P-II-D-2-a-(6). The walls, floors, and ceilings of the 
    greenhouse shall be constructed to form a sealed internal shell that 
    facilitates fumigation and is animal and arthropod-proof. These 
    internal surfaces shall be resistant to penetration and degradation by 
    liquids and chemicals to facilitate cleaning and decontamination of the 
    area. All penetrations into these structures and surfaces (e.g., 
    plumbing and utilities) shall be sealed.
        Appendix P-II-D-2-a-(7). Bench tops and other work surfaces shall 
    have seamless surfaces impervious to water and resistant to acids, 
    alkalis, organic solvents, and moderate heat.
        Appendix P-II-D-2-a-(8). A double-door autoclave, fumigation 
    chamber, or ventilated airlock shall be provided for passage of all 
    materials, supplies, or equipment that are not brought into the 
    greenhouse facility through the change room.
    Appendix P-II-D-2-b. Autoclaves (BL4-P)
        Appendix P-II-D-2-b-(1). A double-door autoclave shall be provided 
    for the decontamination of materials removed from the greenhouse 
    facility. The autoclave door, which opens to the area external to the 
    greenhouse facility, shall be sealed to the outer wall and 
    automatically controlled so that it can only be opened upon completion 
    of the sterilization cycle.
    Appendix P-II-D-2-c. Supply and Exhaust Air Ventilation Systems       
    (BL4-P)
        Appendix P-II-D-2-c-(1). An individual supply and exhaust air 
    ventilation system shall be provided. The system shall maintain 
    pressure differentials and directional airflow as required to assure 
    inward (or zero) airflow from areas outside of the greenhouse. 
    Differential pressure transducers shall be used to sense pressure 
    levels. If a system malfunctions, the transducers shall sound an alarm. 
    A backup source of power should be considered. The supply and exhaust 
    airflow shall be interlocked to assure inward (or zero) airflow at all 
    times. The integrity of the greenhouse shall have an air leak rate 
    (decay rate) not to exceed 7 percent per minute (logarithm of pressure 
    against time) over a 20-minute period at 2 inches of water gauge 
    pressure. Nominally, this is 0.05 inches of water gauge pressure loss 
    in 1 minute at 2 inches water gauge pressure.
        Appendix P-II-D-2-c-(2). Exhaust air from the greenhouse facility 
    shall be filtered through high efficiency particulate air/HEPA filters 
    and discharged to the outside and dispersed away from occupied 
    buildings and air intakes. Filter chambers shall be designed to allow 
    in situ decontamination before filters are removed and to facilitate 
    certification testing after they are replaced. HEPA filters shall be 
    provided to treat air supplied to the greenhouse facility. HEPA filters 
    shall be certified annually.
    Appendix P-II-D-2-d. Other (BL4-P)
        Appendix P-II-D-2-d-(1). Sewer vents and other ventilation lines 
    contain high efficiency particulate air/HEPA filters. HEPA filters 
    shall be certified annually.
        Appendix P-II-D-2-d-(2). A pass-through dunk tank, fumigation 
    chamber, or an equivalent method of decontamination shall be provided 
    to ensure decontamination of materials and equipment that cannot be 
    decontaminated in the autoclave.
        Appendix P-II-D-2-d-(3). Liquid effluent from sinks, floors, and 
    autoclave chambers shall be decontaminated by heat or chemical 
    treatment before being released from the maximum containment greenhouse 
    facility. Liquid wastes from shower rooms and toilets may be 
    decontaminated by heat or chemical treatment. Autoclave and chemical 
    decontamination of liquid wastes shall be evaluated by appropriate 
    standard procedures for autoclaved wastes. Decontamination shall be 
    evaluated mechanically and biologically using a recording thermometer 
    and an indicator microorganism with a defined heat susceptibility 
    pattern. If liquid wastes are decontaminated with chemical 
    disinfectants, the chemicals used must have demonstrated efficacy 
    against the target or indicator microorganisms.
        Appendix P-II-D-2-d-(4). If there is a central vacuum system, it 
    shall not serve areas outside of the greenhouse facility. In-line high 
    efficiency particulate air/HEPA filters shall be placed as near as 
    practicable to each use point or vacuum service cock. Other liquid and 
    gas services to the greenhouse facility shall be protected by devices 
    that prevent back-flow. HEPA filters shall be certified annually.
    Appendix P-III. Biological Containment Practices
        Appropriate selection of the following biological containment 
    practices may be used to meet the containment requirements for a given 
    organism. The present list is not exhaustive; there may be other ways 
    of preventing effective dissemination that could possibly lead to the 
    establishment of the organism or its genetic material in the 
    environment resulting in deleterious consequences to managed or natural 
    ecosystems.
    Appendix P-III-A. Biological Containment Practices (Plants)
        Appendix P-III-A-1. Effective dissemination of plants by pollen or 
    seed can be prevented by one or more of the following procedures: (i) 
    Cover the reproductive structures to prevent pollen dissemination at 
    flowering and seed dissemination at maturity; (ii) remove reproductive 
    structures by employing male sterile strains, or harvest the plant 
    material prior to the reproductive stage; (iii) ensure that 
    experimental plants flower at a time of year when cross-fertile plants 
    are not flowering within the normal pollen dispersal range of the 
    experimental plant; or (iv) ensure that cross-fertile plants are not 
    growing within the known pollen dispersal range of the experimental 
    plant.
    Appendix P-III-B. Biological Containment Practices (Microorganisms)
        Appendix P-III-B-1. Effective dissemination of microorganisms 
    beyond the confines of the greenhouse can be prevented by one or more 
    of the following procedures: (i) Confine all operations to injections 
    of microorganisms or other biological procedures (including genetic 
    manipulation) that limit replication or reproduction of viruses and 
    microorganisms or sequences derived from microorganisms, and confine 
    these injections to internal plant parts or adherent plant surfaces; 
    (ii) ensure that organisms, which can serve as hosts or promote the 
    transmission of the virus or microorganism, are not present within the 
    farthest distance that the airborne virus or microorganism may be 
    expected to be effectively disseminated; (iii) conduct experiments at a 
    time of year when plants that can serve as hosts are either not growing 
    or are not susceptible to productive infection; (iv) use viruses and 
    other microorganisms or their genomes that have known arthropod or 
    animal vectors, in the absence of such vectors; (v) use microorganisms 
    that have an obligate association with the plant; or (vi) use 
    microorganisms that are genetically disabled to minimize survival 
    outside of the research facility and whose natural mode of transmission 
    requires injury of the target organism, or assures that inadvertent 
    release is unlikely to initiate productive infection of organisms 
    outside of the experimental facility.
    Appendix P-III-C. Biological Containment Practices (Macroorganisms)
        Appendix P-III-C-1. Effective dissemination of arthropods and other 
    small animals can be prevented by using one or more of the following 
    procedures: (i) Use non-flying, flight-impaired, or sterile arthropods; 
    (ii) use non-motile or sterile strains of small animals; (iii) conduct 
    experiments at a time of year that precludes the survival of escaping 
    organisms; (iv) use animals that have an obligate association with a 
    plant that is not present within the dispersal range of the organism; 
    or (v) prevent the escape of organisms present in run-off water by 
    chemical treatment or evaporation of run-off water.
    
    I. Addition of Appendix Q, Physical and Biological Containment for 
    Recombinant DNA Research Involving Animals, to the NIH Guidelines
    
        The following new appendix, Appendix Q, reads as follows:
        Appendix Q specifies containment and confinement practices for 
    research involving whole animals, both those in which the animal's 
    genome has been altered by stable introduction of recombinant DNA, or 
    DNA derived therefrom, into the germ-line (transgenic animals) and 
    experiments involving viable recombinant DNA-modified microorganisms 
    tested on whole animals. The appendix applies to animal research 
    activities with the following modifications:
        Appendix Q shall supersede Appendix G when research animals are of 
    a size or have growth requirements that preclude the use of containment 
    for laboratory animals. Some animals may require other types of 
    containment (see Appendix Q-III-D). The animals covered in Appendix Q 
    are those species normally categorized as animals including but not 
    limited to cattle, swine, sheep, goats, horses, and poultry.
        The Institutional Biosafety Committee shall include at least one 
    scientist with expertise in animal containment principles when 
    experiments utilizing Appendix Q require Institutional Biosafety 
    Committee prior approval.
        The institution shall establish and maintain a health surveillance 
    program for personnel engaged in animal research involving viable 
    recombinant DNA-containing microorganisms that require Biosafety Level 
    (BL) 3 or greater containment in the laboratory.
    Appendix Q-I. General Considerations
    Appendix Q-I-A. Containment Levels
        The containment levels required for research involving recombinant 
    DNA associated with or in animals is based on classification of 
    experiments in Section III. For the purpose of animal research, four 
    levels of containment are established. These are referred to as BL1-
    Animals (N), BL2-N, BL3-N, and BL4-N and are described in the following 
    sections of Appendix Q. The descriptions include: (i) standard 
    practices for physical and biological containment, and (ii) animal 
    facilities.
    Appendix Q-I-B. Disposal of Animals (BL1-N through BL4-N)
        Appendix Q-I-B-1. When an animal covered by Appendix Q containing 
    recombinant DNA or a recombinant DNA-derived organism is euthanized or 
    dies, the carcass shall be disposed of to avoid its use as food for 
    human beings or animals unless food use is specifically authorized by 
    an appropriate Federal agency.
        Appendix Q-I-B-2. A permanent record shall be maintained of the 
    experimental use and disposal of each animal or group of animals.
    Appendix Q-II. Physical and Biological Containment Levels
    Appendix Q-II-A. Biosafety Level 1 - Animals (BL1-N)
    Appendix Q-II-A-1. Standard Practices (BL1-N)
    Appendix Q-II-A-1-a. Animal Facility Access (BL1-N)
        Appendix Q-II-A-1-a-(1). The containment area shall be locked.
        Appendix Q-II-A-1-a-(2). Access to the containment area shall be 
    limited or restricted when experimental animals are being held.
        Appendix Q-II-A-1-a-(3). The containment area shall be patrolled or 
    monitored at frequent intervals.
    Appendix Q-II-A-1-b. Other (BL1-N)
        Appendix Q-II-A-1-b-(1). All genetically engineered neonates shall 
    be permanently marked within 72 hours after birth, if their size 
    permits. If their size does not permit marking, their containers should 
    be marked. In addition, transgenic animals should contain distinct and 
    biochemically assayable DNA sequences that allow identification of 
    transgenic animals from among non- transgenic animals.
        Appendix Q-II-A-1-b-(2) A double barrier shall be provided to 
    separate male and female animals unless reproductive studies are part 
    of the experiment or other measures are taken to avoid reproductive 
    transmission. Reproductive incapacitation may be used.
        Appendix Q-II-A-1-b-(3). The containment area shall be in 
    accordance with state and Federal laws and animal care requirements.
    Appendix Q-II-A-2. Animal Facilities (BL1-N)
        Appendix Q-II-A-2-(a). Animals shall be confined to securely fenced 
    areas or be in enclosed structures (animal rooms) to minimize the 
    possibility of theft or unintentional release.
    Appendix Q-II-B. Biosafety Level 2 - Animals (BL2-N) (see Appendix Q-
    III-A)
    Appendix Q-II-B-1. Standard Practices (BL2-N)
    Appendix Q-II-B-1-a. Animal Facility Access (BL2-N)
        Appendix Q-II-B-1-a-(1). The containment area shall be locked.
        Appendix Q-II-B-1-a-(2). The containment area shall be patrolled or 
    monitored at frequent intervals.
        Appendix Q-II-B-1-a-(3). The containment building shall be 
    controlled and have a locking access.
        Appendix Q-II-B-1-a-(4). The Animal Facility Director shall 
    establish policies and procedures whereby only persons who have been 
    advised of the potential hazard and who meet any specific entry 
    requirements (e.g., vaccination) may enter the laboratory or animal 
    rooms.
        Appendix Q-II-B-1-a-(5). Animals of the same or different species, 
    which are not involved in the work being performed, shall not be 
    permitted in the animal area.
        Appendix Q-II-B-1-b. Decontamination and Inactivation (BL2-N)
        Appendix Q-II-B-1-b-(1). Contaminated materials that are 
    decontaminated at a site away from the laboratory shall be placed in a 
    closed durable leak-proof container prior to removal from the 
    laboratory.
        Appendix Q-II-B-1-b-(2). Needles and syringes shall be promptly 
    placed in a puncture-resistant container and decontaminated, preferably 
    by autoclaving, before discard or reuse.
    Appendix Q-II-B-1-c. Signs (BL2-N)
        Appendix Q-II-B-1-c-(1). When the animal research requires special 
    provisions for entry (e.g., vaccination), a warning sign incorporating 
    the universal biosafety symbol shall be posted on all access doors to 
    the animal work area. The sign shall indicate: (i) The agent, (ii) the 
    animal species, (iii) the name and telephone number of the Animal 
    Facility Director or other responsible individual, and (iv) any special 
    requirements for entering the laboratory.
    Appendix Q-II-B-1-d. Protective Clothing (BL2-N)
        Appendix Q-II-B-1-d-(1). Laboratory coats, gowns, smocks, or 
    uniforms shall be worn while in the animal area or attached laboratory. 
    Before entering non-laboratory areas (e.g., cafeteria, library, 
    administrative offices), protective clothing shall be removed and kept 
    in the work entrance area.
        Appendix Q-II-B-1-d-(2). Special care shall be taken to avoid skin 
    contamination with microorganisms containing recombinant DNA. 
    Impervious and/or protective gloves shall be worn when handling 
    experimental animals and when skin contact with an infectious agent is 
    unavoidable.
    Appendix Q-II-B-1-e. Records (BL2-N)
        Appendix Q-II-B-1-e-(1). Any incident involving spills and 
    accidents that result in environmental release or exposures of animals 
    or laboratory workers to organisms containing recombinant DNA molecules 
    shall be reported immediately to the Animal Facility Director, 
    Institutional Biosafety Committee, NIH/ORDA, and other appropriate 
    authorities (if applicable). Reports to the NIH/ORDA shall be sent to 
    the Office of Recombinant DNA Activities, National Institutes of 
    Health, Building 31, Room 4B11, Bethesda, Maryland 20892, (301) 496-
    9838. Medical evaluation, surveillance, and treatment shall be provided 
    as appropriate and written records maintained. If necessary, the area 
    shall be appropriately decontaminated.
    Appendix Q-II-B-1-e-(2). When appropriate and giving consideration to 
    the agent handled, baseline serum samples shall be collected and stored 
    for animal care and other at-risk personnel. Additional serum specimens 
    may be collected periodically depending on the agent handled and the 
    function of the animal facility.
    Appendix Q-II-B-1-f. Transfer of Materials (BL2-N)
        Appendix Q-II-B-1-f-(1). Biological materials removed from the 
    animal containment area in a viable or intact state shall be 
    transferred to a non-breakable sealed primary container and then 
    enclosed in a non-breakable sealed secondary container. All containers, 
    primary and secondary, shall be disinfected before removal from the 
    animal facility. Advance approval for transfer of material shall be 
    obtained from the Animal Facility Director. Packages containing viable 
    agents may only be opened in a facility having an equivalent or higher 
    level of physical containment unless the agent is biologically 
    inactivated or incapable of reproduction.
    Appendix Q-II-B-1-g. Other (BL2-N)
        Appendix Q-II-B-1-g-(1). All genetically engineered neonates shall 
    be permanently marked within 72 hours after birth, if their size 
    permits. If their size does not permit marking, their containers should 
    be marked. In addition, transgenic animals should contain distinct and 
    biochemically assayable DNA sequences that allow identification of 
    transgenic animals from among non-transgenic animals.
        Appendix Q-II-B-1-g-(2). Needles and syringes shall be used only 
    for parenteral injection and aspiration of fluids from laboratory 
    animals and diaphragm bottles. Only needle-locking syringes or 
    disposable syringe-needle units (i.e., needle is integral to the 
    syringe) shall be used for the injection or aspiration of fluids 
    containing organisms that contain recombinant DNA. Extreme caution 
    shall be used when handling needles and syringes to avoid 
    autoinoculation and the generation of aerosols during use and disposal. 
    Following use, needles shall not be bent, sheared, replaced in the 
    needle sheath or guard, or removed from the syringe. Needles and 
    syringes shall be promptly placed in a puncture-resistant container and 
    decontaminated, preferably by autoclaving, before discard or reuse.
        Appendix Q-II-B-1-g-(3). Appropriate steps should be taken to 
    prevent horizontal transmission or exposure of laboratory personnel. If 
    the agent used as a vector is known to be transmitted by a particular 
    route (e.g., arthropods), special attention should be given to 
    preventing spread by that route. In the absence of specific knowledge 
    of a particular route of transmission, all potential means of 
    horizontal transmission (e.g., arthropods, contaminated bedding, or 
    animal waste, etc.) should be prevented.
        Appendix Q-II-B-1-g-(4). Eating, drinking, smoking, and applying 
    cosmetics shall not be permitted in the work area.
        Appendix Q-II-B-1-g-(5). Individuals who handle materials and 
    animals containing recombinant DNA molecules shall be required to wash 
    their hands before exiting the containment area.
        Appendix Q-II-B-1-g-(6). A double barrier shall be provided to 
    separate male and female animals unless reproductive studies are part 
    of the experiment or other measures are taken to avoid reproductive 
    transmission. Reproductive incapacitation may be used.
        Appendix Q-II-B-1-g-(7). The containment area shall be in 
    accordance with state and Federal laws and animal care requirements.
        Appendix Q-II-B-1-g-(8). A biosafety manual shall be prepared or 
    adopted. Personnel shall be advised of special hazards and required to 
    read and follow instructions on practices and procedures.
    Appendix Q-II-B-2. Animal Facilities (BL2-N)
        Appendix Q-II-B-2-a. Animals shall be contained within an enclosed 
    structure (animal room or equivalent) to minimize the possibility of 
    theft or unintentional release and to avoid arthropod access. The 
    special provision to avoid the entry or escape of arthropods from the 
    animal areas may be waived if the agent in use is not known to be 
    transmitted by arthropods.
        Appendix Q-II-B-2-b. Surfaces shall be impervious to water and 
    resistant to acids, alkalis, organic solvents, and moderate heat.
        Appendix Q-II-B-2-c. The animal containment area shall be designed 
    so that it can be easily cleaned.
        Appendix Q-II-B-2-d. Windows that open shall be fitted with fly 
    screens.
        Appendix Q-II-B-2-e. An autoclave shall be available for 
    decontamination of laboratory wastes.
        Appendix Q-II-B-2-f. If arthropods are used in the experiment or 
    the agent under study can be transmitted by an arthropod, interior work 
    areas shall be appropriately screened (52 mesh). All perimeter joints 
    and openings shall be sealed and additional arthropod control 
    mechanisms used to minimize arthropod entry and propagation, including 
    appropriate screening of access doors or the equivalent.
    Appendix Q-II-C. Biosafety Level 3--Animals (BL3-N) (See Appendix Q-
    III-B)
    Appendix Q-II-C-1. Standard Practices (BL3-N)
    Appendix Q-II-C-1-a. Animal Facility Access (BL3-N)
        Appendix Q-II-C-1-a-(1). The containment area shall be locked.
        Appendix Q-II-C-1-a-(2). The containment area shall be patrolled or 
    monitored at frequent intervals.
        Appendix Q-II-C-1-a-(3). The containment building shall be 
    controlled and have a locking access.
        Appendix Q-II-C-1-a-(4). The Animal Facility Director shall 
    establish policies and procedures whereby only persons who have been 
    advised of the potential hazard and who meet any specific entry 
    requirements (e.g., vaccination) shall enter the laboratory or animal 
    rooms.
        Appendix Q-II-C-1-a-(5). Animal room doors, gates, or other 
    closures shall be kept closed when experiments are in progress.
    Appendix Q-II-C-1-b. Decontamination and Inactivation (BL3-N)
        Appendix Q-II-C-1-b-(1). The work surfaces of containment equipment 
    shall be decontaminated when work with organisms containing recombinant 
    DNA molecules is finished. Where feasible, plastic-backed paper 
    toweling shall be used on nonporous work surfaces to facilitate clean-
    up.
        Appendix Q-II-C-1-b-(2). All animals shall be euthanized at the end 
    of their experimental usefulness and the carcasses decontaminated 
    before disposal in an approved manner.
        Appendix Q-II-C-1-b-(3). Needles and syringes shall be promptly 
    placed in a puncture-resistant container and decontaminated, preferably 
    by autoclaving, before discard or reuse.
        Appendix Q-II-C-1-b-(4). Special safety testing, decontamination 
    procedures, and Institutional Biosafety Committee approval shall be 
    required to transfer agents or tissue/organ specimens from a BL3-N 
    animal facility to a facility with a lower containment classification.
        Appendix Q-II-C-1-b-(5). Liquid effluent from containment 
    equipment, sinks, biological safety cabinets, animal rooms, primary 
    barriers, floor drains, and sterilizers shall be decontaminated by heat 
    treatment before being released into the sanitary system. The procedure 
    used for heat decontamination of liquid wastes shall be monitored with 
    a recording thermometer. The effectiveness of the heat decontamination 
    process system shall be revalidated every 30 days with an indicator 
    organism.
    Appendix Q-II-C-1-c. Signs (BL3-N)
        Appendix Q-II-C-1-c-(1). When the animal research requires special 
    provisions for entry (e.g., vaccination), a warning sign incorporating 
    the universal biosafety symbol shall be posted on all access doors to 
    the animal work area. The sign shall indicate: (i) The agent, (ii) the 
    animal species, (iii) the name and telephone number of the Animal 
    Facility Director or other responsible individual, and (iv) any special 
    requirements for entering the laboratory.
    Appendix Q-II-C-1-d. Protective Clothing (BL3-N)
        Appendix Q-II-C-1-d-(1). Full protective clothing that protects the 
    individual (e.g., scrub suits, coveralls, uniforms) shall be worn in 
    the animal area. Clothing shall not be worn outside the animal 
    containment area and shall be decontaminated before laundering or 
    disposal. Personnel shall be required to shower before exiting the BL3-
    N area and wearing of personal clothing.
        Appendix Q-II-C-1-d-(2). Special care shall be taken to avoid skin 
    contamination with microorganisms containing recombinant DNA. 
    Impervious and/or protective gloves shall be worn when handling 
    experimental animals and when skin contact with an infectious agent is 
    unavoidable.
        Appendix Q-II-C-1-d-(3). Appropriate respiratory protection shall 
    be worn in rooms containing experimental animals.
    Appendix Q-II-C-1-e. Records (BL3-N)
        Appendix Q-II-C-1-e-(1). Documents regarding experimental animal 
    use and disposal shall be maintained in a permanent record book.
        Appendix Q-II-C-1-e-(2). Any incident involving spills and 
    accidents that result in environmental release or exposure of animals 
    or laboratory workers to organisms containing recombinant DNA shall be 
    reported immediately to the Biological Safety Office, Animal Facility 
    Director, Institutional Biosafety Committee, NIH/ORDA, and other 
    appropriate authorities (if applicable). Reports to the NIH/ORDA shall 
    be sent to the Office of Recombinant DNA Activities, National 
    Institutes of Health, Building 31, Room 4B11, Bethesda, Maryland 20892, 
    (301) 496-9838. Medical evaluation, surveillance, and treatment shall 
    be provided as appropriate and written records maintained. If 
    necessary, the area shall be appropriately decontaminated.
        Appendix Q-II-C-1-e-(3). When appropriate and giving consideration 
    to the agent handled, baseline serum samples shall be collected and 
    stored for animal care and other at-risk personnel. Additional serum 
    specimens may be collected periodically depending on the agent handled 
    or the function of the facility.
    Appendix Q-II-C-1-f. Transfer of Materials (BL3-N)
        Appendix Q-II-C-1-f-(1). Biological materials removed from the 
    animal containment laboratory in a viable or intact state shall be 
    transferred to a non- breakable sealed primary container and then 
    enclosed in a non-breakable sealed secondary container. All containers, 
    primary and secondary, shall be disinfected before removal from the 
    animal facility. Advance approval for transfer of material shall be 
    obtained from the Animal Facility Director. Packages containing viable 
    agents may be opened only in a facility having an equivalent or higher 
    level of physical containment unless the agent is biologically 
    inactivated or incapable of reproduction.
        Appendix Q-II-C-1-f-(2). Special safety testing, decontamination 
    procedures, and Institutional Biosafety Committee approval shall be 
    required to transfer agents or tissue/organ specimens from a BL3-N 
    animal facility to a facility with a lower containment classification.
    Appendix Q-II-C-1-g. Other (BL3-N)
        Appendix Q-II-C-1-g-(1). All genetically engineered neonates shall 
    be permanently marked within 72 hours after birth, if their size 
    permits. If their size does not permit marking, their containers should 
    be marked. In addition, transgenic animals should contain distinct and 
    biochemically assayable DNA sequences that allow identification of 
    transgenic animals from among nontransgenic animals.
        Appendix Q-II-C-1-g-(2). Appropriate steps should be taken to 
    prevent horizontal transmission or exposure of laboratory personnel. If 
    the agent used as the vector is known to be transmitted by a particular 
    route (e.g., arthropods), special attention should be given to 
    preventing spread by that route. In the absence of specific knowledge 
    of a particular route of transmission, all potential means of 
    horizontal transmission (e.g., arthropods, contaminated bedding, or 
    animal waste) should be prevented.
        Appendix Q-II-C-1-g-(3). Eating, drinking, smoking, and applying 
    cosmetics shall not be permitted in the work area.
        Appendix Q-II-C-1-g-(4). Individuals who handle materials and 
    animals containing recombinant DNA molecules shall be required to wash 
    their hands before exiting the containment area.
        Appendix Q-II-C-1-g-(5). Experiments involving other organisms that 
    require containment levels lower than BL3-N may be conducted in the 
    same area concurrently with experiments requiring BL3-N containment 
    provided that they are conducted in accordance with BL3-N practices.
        Appendix Q-II-C-1-g-(6). Animal holding areas shall be cleaned at 
    least once a day and decontaminated immediately following any spill of 
    viable materials.
        Appendix Q-II-C-1-g-(7). All procedures shall be performed 
    carefully to minimize the creation of aerosols.
        Appendix Q-II-C-1-g-(8). A double barrier shall be provided to 
    separate male and female animals unless reproductive studies are part 
    of the experiment or other measures are taken to avoid reproductive 
    transmission. Reproductive incapacitation may be used.
        Appendix Q-II-C-1-g-(9). The containment area shall be in 
    accordance with state and Federal laws and animal care requirements.
        Appendix Q-II-C-1-g-(10). All animals shall be euthanized at the 
    end of their experimental usefulness and the carcasses decontaminated 
    before disposal in an approved manner.
        Appendix Q-II-C-1-g-(11). Personnel shall be required to shower 
    before exiting the BL3-N area and wearing personal clothing.
        Appendix Q-II-C-1-g-(12). Animals of the same or different species, 
    which are not involved in the work being performed, shall not be 
    permitted in the animal area.
        Appendix Q-II-C-1-g-(13). Needles and syringes shall be used only 
    for parenteral injection and aspiration of fluids from laboratory 
    animals and diaphragm bottles. Only needle-locking syringes or 
    disposable syringe-needle units (i.e., needle is integral to the 
    syringe) shall be used for the injection or aspiration of fluids 
    containing organisms that contain recombinant DNA. Extreme caution 
    shall be used when handling needles and syringes to avoid 
    autoinoculation and the generation of aerosols during use and disposal. 
    Following use, needles shall not be bent, sheared, replaced in the 
    needle sheath or guard or removed from the syringe. The needles and 
    syringes shall be promptly placed in a puncture-resistant container and 
    decontaminated, preferably by autoclaving, before discard or reuse.
        Appendix Q-II-C-1-g-(14). A biosafety manual shall be prepared or 
    adopted. Personnel shall be advised of special hazards and required to 
    read and follow instructions on practices and procedures.
    Appendix Q-II-C-2. Animal Facilities (BL3-N)
        Appendix Q-II-C-2-a. Animals shall be contained within an enclosed 
    structure (animal room or equivalent) to minimize the possibility of 
    theft or unintentional release and avoid arthropod access. The special 
    provision to avoid the entry or escape of arthropods from the animal 
    areas may be waived if the agent in use is not known to be transmitted 
    by arthropods.
        Appendix Q-II-C-2-b. The interior walls, floors, and ceilings shall 
    be impervious to water and resistant to acids, alkalis, organic 
    solvents, and moderate heat, to facilitate cleaning. Penetrations in 
    these structures and surfaces (e.g., plumbing and utilities) shall be 
    sealed.
        Appendix Q-II-C-2-c. Windows in the animal facility shall be 
    closed, sealed, and breakage resistant (e.g., double-pane tempered 
    glass or equivalent). The need to maintain negative pressure should be 
    considered when constructing or renovating the animal facility.
        Appendix Q-II-C-2-d. An autoclave, incinerator, or other effective 
    means to decontaminate animals and waste shall be available, preferably 
    within the containment area. If feasible, a double-door autoclave is 
    preferred and should be positioned to allow removal of material from 
    the containment area.
        Appendix Q-II-C-2-e. If arthropods are used in the experiment or 
    the agent under study can be transmitted by an arthropod, the interior 
    work area shall be appropriately screened (52 mesh). All perimeter 
    joints and openings shall be sealed, and additional arthropod control 
    mechanisms used to minimize arthropod entry and propagation, including 
    appropriate screening, or the equivalent of access doors.
        Appendix Q-II-C-2-f. Access doors to the containment area shall be 
    self-closing.
        Appendix Q-II-C-2-g. The animal area shall be separated from all 
    other areas. Passage through two sets of doors shall be the basic 
    requirement for entry into the animal area from access corridors or 
    other contiguous areas. The animal containment area shall be physically 
    separated from access corridors and other laboratories or areas by a 
    double-door clothes change room, equipped with integral showers and 
    airlock.
        Appendix Q-II-C-2-h. Liquid effluent from containment equipment, 
    sinks, biological safety cabinets, animal rooms, primary barriers, 
    floor drains, and sterilizers shall be decontaminated by heat treatment 
    before being released into the sanitary system. The procedure used for 
    heat decontamination of liquid wastes shall be monitored with a 
    recording thermometer. The effectiveness of the heat decontamination 
    process system shall be revalidated every 30 days with an indicator 
    organism.
        Appendix Q-II-C-2-i. An exhaust air ventilation system shall be 
    provided. This system shall create directional airflow that draws air 
    into the animal room through the entry area. The building exhaust, or 
    the exhaust from primary containment units, may be used for this 
    purpose if the exhaust air is discharged to the outside and shall be 
    dispersed away from occupied areas and air intakes. Personnel shall 
    verify that the direction of the airflow (into the animal room) is 
    proper.
        Appendix Q-II-C-2-j. If the agent is transmitted by aerosol, then 
    the exhaust air shall pass through a high efficiency particulate air/
    HEPA filter.
        Appendix Q-II-C-2-k. Vacuum lines shall be protected with high 
    efficiency particulate air/HEPA filters and liquid disinfectant traps.
        Appendix Q-II-C-2-l. In lieu of open housing in the special animal 
    room, animals held in a BL3-N area may be housed in partial-containment 
    caging systems (e.g., Horsfall units or gnotobiotic systems, or other 
    special containment primary barriers). Prudent judgment must be 
    exercised to implement this ventilation system (e.g., animal species) 
    and its discharge location.
        Appendix Q-II-C-2-m. Each animal area shall contain a foot, elbow, 
    or automatically operated sink for hand washing. The sink shall be 
    located near the exit door.
        Appendix Q-II-C-2-n. Restraining devices for animals may be 
    required to avoid damage to the integrity of the animal containment 
    facility.
    Appendix Q-II-D. Biosafety Level 4--Animals (BL4-N) (See Appendix Q-
    III-C)
    Appendix Q-II-D-1. Standard Practices (BL4-N)
    Appendix Q-II-D-1-a. Animal Facility Access (BL4-N)
        Appendix Q-II-D-1-a-(1). Individuals under 16 years of age shall 
    not be permitted to enter the animal area.
        Appendix Q-II-D-1-a-(2). The containment area shall be locked.
        Appendix Q-II-D-1-a-(3). The containment area shall be patrolled or 
    monitored at frequent intervals.
        Appendix Q-II-D-1-a-(4). The containment building shall be 
    controlled and have a locking access.
        Appendix Q-II-D-1-a-(5). The Animal Facility Director shall 
    establish policies and procedures whereby only persons who have been 
    advised of the potential hazard and who meet any specific entry 
    requirements (e.g., vaccination) may enter the laboratory or animal 
    room.
        Appendix Q-II-D-1-a-(6). Individuals shall enter and exit the 
    animal facility only through the clothing change and shower rooms.
        Appendix Q-II-D-1-a-(7). Personnel shall use the airlocks to enter 
    or exit the laboratory only in an emergency.
        Appendix Q-II-D-1-a-(8). Animal room doors, gates, and other 
    closures shall be kept closed when experiments are in progress.
        Appendix Q-II-D-1-b. Decontamination and Inactivation (BL4-N)
        Appendix Q-II-D-1-b-(1). All contaminated liquid or solid wastes 
    shall be decontaminated before disposal.
        Appendix Q-II-D-1-b-(2). The work surfaces and containment 
    equipment shall be decontaminated when work with organisms containing 
    recombinant DNA molecules is finished. Where feasible, plastic-backed 
    paper toweling shall be used on nonporous work surfaces to facilitate 
    clean-up.
        Appendix Q-II-D-1-b-(3). All wastes from animal rooms and 
    laboratories shall be appropriately decontaminated before disposal in 
    an approved manner.
        Appendix Q-II-D-1-b-(4). No materials, except for biological 
    materials that are to remain in a viable or intact state, shall be 
    removed from the maximum containment laboratory unless they have been 
    autoclaved or decontaminated.
        Equipment or material that might be damaged by high temperatures or 
    steam shall be decontaminated by gaseous or vapor methods in an airlock 
    or chamber designed for this purpose.
        Appendix Q-II-D-1-b-(5). When ventilated suits are required, the 
    animal personnel shower entrance/exit area shall be equipped with a 
    chemical disinfectant shower to decontaminate the surface of the suit 
    before exiting the area. A neutralization or water dilution device 
    shall be integral with the chemical disinfectant discharge piping 
    before entering the heat sterilization system. Entry to this area shall 
    be through an airlock fitted with airtight doors.
        Appendix Q-II-D-1-b-(6). Needles and syringes shall be promptly 
    placed in a puncture-resistant container and decontaminated, preferably 
    by autoclaving, before discard or reuse.
        Appendix Q-II-D-1-b-(7). Supplies and materials needed in the 
    animal facility shall be brought in by way of the double-door 
    autoclave, fumigation chamber, or airlock that shall be appropriately 
    decontaminated between each use.
        Appendix Q-II-D-1-b-(8). An autoclave, incinerator, or other 
    effective means to decontaminate animals and wastes shall be available, 
    preferably within the containment area. If feasible, a double-door 
    autoclave is preferred and should be positioned to allow removal of 
    material from the containment area.
        Appendix Q-II-D-1-b-(9). Liquid effluent from containment 
    equipment, sinks, biological safety cabinets, animal rooms, primary 
    barriers, floor drains, and sterilizers shall be decontaminated by heat 
    treatment before being released into the sanitary system. Liquid wastes 
    from shower rooms and toilets shall be decontaminated with chemical 
    disinfectants or heat by methods demonstrated to be effective. The 
    procedure used for heat decontamination of liquid wastes shall be 
    monitored with a recording thermometer. The effectiveness of the heat 
    decontamination process system shall be revalidated every 30 days with 
    an indicator organism. Liquid wastes from the shower shall be 
    chemically decontaminated using an Environmental Protection Agency-
    approved germicide. The efficacy of the chemical treatment process 
    shall be validated with an indicator organism. Chemical disinfectants 
    shall be neutralized or diluted before release into general effluent 
    waste systems.
    Appendix Q-II-D-1-c. Signs (BL4-N)
        Appendix Q-II-D-1-c-(1). When the animal research requires special 
    provisions for entry (e.g., vaccination), a warning sign incorporating 
    the universal biosafety symbol shall be posted on all access doors to 
    the animal work area. The sign shall indicate: (i) The agent, (ii) the 
    animal species, (iii) the name and telephone number of the Animal 
    Facility Director, or other responsible individual, and (iv) any 
    special requirements for entering the laboratory.
    Appendix Q-II-D-1-d. Protective Clothing (BL4-N)
        Appendix Q-II-D-1-d-(1). Individuals shall enter and exit the 
    animal facility only through the clothing change and shower rooms. 
    Street clothing shall be removed and kept in the outer clothing change 
    room. Complete laboratory clothing (may be disposable), including 
    undergarments, pants, shirts, jump suits, and shoes shall be provided 
    for all personnel entering the animal facility. When exiting the BL4-N 
    area and before proceeding into the shower area, personnel shall remove 
    their laboratory clothing in the inner change room. All laboratory 
    clothing shall be autoclaved before laundering. Personnel shall shower 
    each time they exit the animal facility.
        Appendix Q-II-D-1-d-(2). A ventilated head-hood or a one-piece 
    positive pressure suit, which is ventilated by a life-support system, 
    shall be worn by all personnel entering rooms that contain experimental 
    animals when appropriate. When ventilated suits are required, the 
    animal personnel shower entrance/exit area shall be equipped with a 
    chemical disinfectant shower to decontaminate the surface of the suit 
    before exiting the area. A neutralization or water dilution device 
    shall be integral with the chemical disinfectant discharge piping 
    before entering the heat sterilization system. Entry to this area shall 
    be through an airlock fitted with airtight doors.
        Appendix Q-II-D-1-d-(3). Appropriate respiratory protection shall 
    be worn in rooms containing experimental animals.
    Appendix Q-II-D-1-e. Records (BL4-N)
        Appendix Q-II-D-1-e-(1). Documents regarding experimental animal 
    use and disposal shall be maintained in a permanent record book.
        Appendix Q-II-D-1-e-(2). A system shall be established for: (i) 
    Reporting laboratory accidents and exposures that are a result of overt 
    exposures to organisms containing recombinant DNA, (ii) employee 
    absenteeism, and (iii) medical surveillance of potential laboratory-
    associated illnesses. Permanent records shall be prepared and 
    maintained. Any incident involving spills and accidents that results in 
    environmental release or exposures of animals or laboratory workers to 
    organisms containing recombinant DNA molecules shall be reported 
    immediately to the Biological Safety Officer, Animal Facility Director, 
    Institutional Biosafety Committee, NIH/ORDA, and other appropriate 
    authorities (if applicable). Reports to the NIH/ORDA shall be sent to 
    the Office of Recombinant DNA Activities, National Institutes of 
    Health, Building 31, Room 4B11, Bethesda, Maryland 20892, (301) 496-
    9838. Medical evaluation, surveillance, and treatment shall be provided 
    as appropriate and written records maintained. If necessary, the area 
    shall be appropriately decontaminated.
        Appendix Q-II-D-1-e-(3). When appropriate and giving consideration 
    to the agents handled, baseline serum samples shall be collected and 
    stored for animal care and other at-risk personnel. Additional serum 
    specimens may be collected periodically depending on the agents handled 
    or the function of the facility.
        Appendix Q-II-D-1-e-(4). A permanent record book indicating the 
    date and time of each entry and exit shall be signed by all personnel.
    Appendix Q-II-D-1-f. Transfer of Materials (BL4-N)
        Appendix Q-II-D-1-f-(1). No materials, except for biological 
    materials that are to remain in a viable or intact state, shall be 
    removed from the maximum containment laboratory unless they have been 
    autoclaved or decontaminated. Equipment or material that might be 
    damaged by high temperatures or steam shall be decontaminated by 
    gaseous or vapor methods in an airlock or chamber designed for this 
    purpose.
        Appendix Q-II-D-1-f-(2). Biological materials removed from the 
    animal maximum containment laboratory in a viable or intact state shall 
    be transferred to a non-breakable sealed primary container and then 
    enclosed in a non-breakable sealed secondary container that shall be 
    removed from the animal facility through a disinfectant dunk tank, 
    fumigation chamber, or an airlock designed for this purpose. Advance 
    approval for transfer of material shall be obtained from the Animal 
    Facility Director. Such packages containing viable agents can only be 
    opened in another BL4-N animal facility if the agent is biologically 
    inactivated or incapable of reproduction. Special safety testing, 
    decontamination procedures, and Institutional Biosafety Committee 
    approval shall be required to transfer agents or tissue/organ specimens 
    from a BL4-N animal facility to one with a lower containment 
    classification.
        Appendix Q-II-D-1-f-(3). Supplies and materials needed in the 
    animal facility shall be brought in by way of the double-door 
    autoclave, fumigation chamber, or airlock that shall be appropriately 
    decontaminated between each use. After securing the outer doors, 
    personnel within the animal facility retrieve the materials by opening 
    the interior doors of the autoclave, fumigation chamber, or airlock. 
    These doors shall be secured after materials are brought into the 
    animal facility.
    Appendix Q-II-D-1-g. Other (BL4-N)
        Appendix Q-II-D-1-g-(1). All genetically engineered neonates shall 
    be permanently marked within 72 hours after birth, if their size 
    permits. If their size does not permit marking, their containers should 
    be marked. In addition, transgenic animals should contain distinct and 
    biochemically assayable DNA sequences that allow identification of 
    transgenic animals from among non-transgenic animals.
        Appendix Q-II-D-1-g-(2). Eating, drinking, smoking, and applying 
    cosmetics shall not be permitted in the work area.
        Appendix Q-II-D-1-g-(3). Individuals who handle materials and 
    animals containing recombinant DNA molecules shall be required to wash 
    their hands before exiting the containment area.
        Appendix Q-II-D-1-g-(4). Experiments involving other organisms that 
    require containment levels lower than BL4-N may be conducted in the 
    same area concurrently with experiments requiring BL4-N containment 
    provided that they are conducted in accordance with BL4-N practices.
        Appendix Q-II-D-1-g-(5). Animal holding areas shall be cleaned at 
    least once a day and decontaminated immediately following any spill of 
    viable materials.
        Appendix Q-II-D-1-g-(6). All procedures shall be performed 
    carefully to minimize the creation of aerosols.
        Appendix Q-II-D-1-g-(7). A double barrier shall be provided to 
    separate male and female animals. Animal isolation barriers shall be 
    sturdy and accessible for cleaning. Reproductive incapacitation may be 
    used.
        Appendix Q-II-D-1-g-(8). The containment area shall be in 
    accordance with state and Federal laws and animal care requirements.
        Appendix Q-II-D-1-g-(9). The life support system for the ventilated 
    suit or head hood is equipped with alarms and emergency back-up air 
    tanks. The exhaust air from the suit area shall be filtered by two sets 
    of high efficiency particulate air/HEPA filters installed in series or 
    incinerated. A duplicate filtration unit, exhaust fan, and an 
    automatically starting emergency power source shall be provided. The 
    air pressure within the suit shall be greater than that of any adjacent 
    area. Emergency lighting and communication systems shall be provided. A 
    double-door autoclave shall be provided for decontamination of waste 
    materials to be removed from the suit area.
        Appendix Q-II-D-1-g-(10). Needles and syringes shall be used only 
    for parenteral injection and aspiration of fluids from laboratory 
    animals and diaphragm bottles. Only needle-locking syringes or 
    disposable syringe-needle units (i.e., needle is integral to the 
    syringe) shall be used for the injection or aspiration of fluids 
    containing organisms that contain recombinant DNA. Extreme caution 
    shall be used when handling needles and syringes to avoid 
    autoinoculation and the generation of aerosols during use and disposal. 
    Following use, needles shall not be bent, sheared, replaced in the 
    needle sheath or guard, or removed from the syringe. The needles and 
    syringes shall be promptly placed in a puncture-resistant container and 
    decontaminated, preferably by autoclaving, before discard or reuse.
        Appendix Q-II-D-1-g-(11). An essential adjunct to the reporting-
    surveillance system is the availability of a facility for quarantine, 
    isolation, and medical care of personnel with potential or known 
    laboratory-associated illnesses.
        Appendix Q-II-D-1-g-(12). A biosafety manual shall be prepared or 
    adopted. Personnel shall be advised of special hazards and required to 
    read and follow instructions on practices and procedures.
        Appendix Q-II-D-1-g-(13). Vacuum lines shall be protected with high 
    efficiency particulate air/HEPA filters and liquid disinfectant traps.
    Appendix Q-II-D-2. Animal Facilities (BL4-N)
        Appendix Q-II-D-2-a. Animals shall be contained within an enclosed 
    structure (animal room or equivalent) to minimize the possibility of 
    theft or unintentional release and avoid arthropod access.
        Appendix Q-II-D-2-b. The interior walls, floors, and ceilings shall 
    be impervious to water and resistant to acids, alkalis, organic 
    solvents, and moderate heat, to facilitate cleaning. Penetrations in 
    these structures and surfaces (e.g., plumbing and utilities) shall be 
    sealed.
        Appendix Q-II-D-2-c. Windows in the animal facility shall be 
    closed, sealed, and breakage resistant (e.g., double-pane tempered 
    glass or equivalent).
        Appendix Q-II-D-2-d. An autoclave, incinerator, or other effective 
    means to decontaminate animals and wastes shall be available, 
    preferably within the containment area. If feasible, a double-door 
    autoclave is preferred and should be positioned to allow removal of 
    material from the containment area.
        Appendix Q-II-D-2-e. Access doors to the containment area shall be 
    self-closing.
        Appendix Q-II-D-2-f. All perimeter joints and openings shall be 
    sealed to form an arthropod-proof structure.
        Appendix Q-II-D-2-g. The BL4-N laboratory provides a double barrier 
    to prevent the release of recombinant DNA containing microorganisms 
    into the environment. Design of the animal facility shall be such that 
    if the barrier of the inner facility is breached, the outer barrier 
    will prevent release into the environment. The animal area shall be 
    separated from all other areas. Passage through two sets of doors shall 
    be the basic requirement for entry into the animal area from access 
    corridors or other contiguous areas. Physical separation of the animal 
    containment area from access corridors or other laboratories or 
    activities shall be provided by a double-door clothes change room 
    equipped with integral showers and airlock.
        Appendix Q-II-D-2-h. A necropsy room shall be provided within the 
    BL4-N containment area.
        Appendix Q-II-D-2-i. Liquid effluent from containment equipment, 
    sinks, biological safety cabinets, animal rooms, primary barriers, 
    floor drains, and sterilizers shall be decontaminated by heat treatment 
    before being released into the sanitary system. Liquid wastes from 
    shower rooms and toilets shall be decontaminated with chemical 
    disinfectants or heat by methods demonstrated to be effective. The 
    procedure used for heat decontamination of liquid wastes shall be 
    monitored with a recording thermometer. The effectiveness of the heat 
    decontamination process system shall be revalidated every 30 days with 
    an indicator organism. Liquid wastes from the shower shall be 
    chemically decontaminated using an Environmental Protection Agency-
    approved germicide.
        The efficacy of the chemical treatment process shall be validated 
    with an indicator organism. Chemical disinfectants shall be neutralized 
    or diluted before release into general effluent waste systems.
        Appendix Q-II-D-2-j. A ducted exhaust air ventilation system shall 
    be provided that creates directional airflow that draws air into the 
    laboratory through the entry area. The exhaust air, which is not 
    recirculated to any other area of the building, shall be discharged to 
    the outside and dispersed away from the occupied areas and air intakes. 
    Personnel shall verify that the direction of the airflow (into the 
    animal room) is proper.
        Appendix Q-II-D-2-k. Exhaust air from BL4-N containment area shall 
    be double high efficiency particulate air/HEPA filtered or treated by 
    passing through a certified HEPA filter and an air incinerator before 
    release to the atmosphere. Double HEPA filters shall be required for 
    the supply air system in a BL4-N containment area.
        Appendix Q-II-D-2-l. All high efficiency particulate air/HEPA 
    filters' frames and housings shall be certified to have no detectable 
    smoke [dioctylphthalate] leaks when the exit face (direction of flow) 
    of the filter is scanned above 0.01 percent when measured by a linear 
    or logarithmic photometer. The instrument must demonstrate a threshold 
    sensitivity of at least 1 x 10-3 micrograms per liter for 0.3 
    micrometer diameter dioctylphthalate particles and a challenge 
    concentration of 80-120 micrograms per liter. The air sampling rate 
    should be at least 1 cfm (28.3 liters per minute).
        Appendix Q-II-D-2-m. If an air incinerator is used in lieu of the 
    second high efficiency particulate air/HEPA filter, it shall be 
    biologically challenged to prove all viable test agents are sterilized. 
    The biological challenge must be minimally 1 x 108 organisms per 
    cubic foot of airflow through the incinerator. It is universally 
    accepted if bacterial spores are used to challenge and verify that the 
    equipment is capable of killing spores, then assurance is provided that 
    all other known agents are inactivated by the parameters established to 
    operate the equipment. Test spores meeting this criterion are Bacillus 
    subtilis var. niger or Bacillus stearothermophilis. The operating 
    temperature of the incinerator shall be continuously monitored and 
    recorded during use.
        Appendix Q-II-D-2-n. All equipment and floor drains shall be 
    equipped with deep traps (minimally 5 inches). Floor drains shall be 
    fitted with isolation plugs or fitted with automatic water fill 
    devices.
        Appendix Q-II-D-2-o. Each animal area shall contain a foot, elbow, 
    or automatically operated sink for hand washing. The sink shall be 
    located near the exit door.
        Appendix Q-II-D-2-p. Restraining devices for animals may be 
    required to avoid damage to the integrity of the containment animal 
    facility.
        Appendix Q-II-D-2-q. The supply water distribution system shall be 
    fitted with a back-flow preventer or break tank.
        Appendix Q-II-D-2-r. All utilities, liquid and gas services, shall 
    be protected with devices that avoid back-flow.
        Appendix Q-II-D-2-s. Sewer and other atmospheric ventilation lines 
    shall be equipped minimally with a single high efficiency particulate/
    HEPA filter. Condensate drains from these type housings shall be 
    appropriately connected to a contaminated or sanitary drain system. The 
    drain position in the housing dictates the appropriate system to be 
    used.
    Appendix Q-III. Footnotes and References for Appendix Q
        Appendix Q-III-A. If recombinant DNA is derived from a Class 2 
    organism requiring BL2 containment, personnel shall be required to have 
    specific training in handling pathogenic agents and directed by 
    knowledgeable scientists.
        Appendix Q-III-B. Personnel who handle pathogenic and potentially 
    lethal agents shall be required to have specific training and be 
    supervised by knowledgeable scientists who are experienced in working 
    with these agents. BL3-N containment also minimizes escape of 
    recombinant DNA-containing organisms from exhaust air or waste material 
    from the containment area.
        Appendix Q-III-C. Classes 4 and 5 microorganisms pose a high level 
    of individual risk for acquiring life-threatening diseases to personnel 
    and/or animals. To import Class 5 agents, special approval must be 
    obtained from U.S. Department of Agriculture, Animal and Plant Health 
    Inspection Service, Import-Export Products, Room 756, Federal Building, 
    6505 Belcrest Road, Hyattsville, Maryland 20782.
        Laboratory staff shall be required to have specific and thorough 
    training in handling extremely hazardous infectious agents, primary and 
    secondary containment, standard and special practices, and laboratory 
    design characteristics. The laboratory staff shall be supervised by 
    knowledgeable scientists who are trained and experienced in working 
    with these agents and in the special containment facilities.
        Within work areas of the animal facility, all activities shall be 
    confined to the specially equipped animal rooms or support areas. The 
    maximum animal containment area and support areas shall have special 
    engineering and design features to prevent the dissemination of 
    microorganisms into the environment via exhaust air or waste disposal.
        Appendix Q-III-D. Other research with non-laboratory animals, which 
    may not appropriately be conducted under conditions described in 
    Appendix Q, may be conducted safely by applying practices routinely 
    used for controlled culture of these biota. In aquatic systems, for 
    example, BL1 equivalent conditions could be met by utilizing growth 
    tanks that provide adequate physical means to avoid the escape of the 
    aquatic species, its gametes, and introduced exogenous genetic 
    material. A mechanism shall be provided to ensure that neither the 
    organisms nor their gametes can escape into the supply or discharge 
    system of the rearing container (e.g., tank, aquarium, etc.) Acceptable 
    barriers include appropriate filtration, irradiation, heat treatment, 
    chemical treatment, etc. Moreover, the top of the rearing container 
    shall be covered to avoid escape of the organism and its gametes. In 
    the event of tank rupture, leakage, or overflow, the construction of 
    the room containing these tanks should prevent the organisms and 
    gametes from entering the building's drains before the organism and its 
    gametes have been inactivated.
        Other types of non-laboratory animals (e.g., nematodes, arthropods, 
    and certain forms of smaller animals) may be accommodated by using the 
    appropriate BL1 through BL4 or BL1-P through BL4-P containment 
    practices and procedures as specified in Appendices G and P.
        OMB's ``Mandatory Information Requirements for Federal Assistance 
    Program Announcements'' (45 FR 39592) requires a statement concerning 
    the official government programs contained in the Catalog of Federal 
    Domestic Assistance. Normally NIH lists in its announcements the number 
    and title of affected individual programs for the guidance of the 
    public. Because the guidance in this notice covers not only virtually 
    every NIH program but also essentially every Federal research program 
    in which DNA recombinant molecule techniques could be used, it has been 
    determined to be not cost effective or in the public interest to 
    attempt to list these programs. Such a list would likely require 
    several additional pages. In addition, NIH could not be certain that 
    every Federal program would be included as many Federal agencies, as 
    well as private organizations, both national and international, have 
    elected to follow the NIH Guidelines. In lieu of the individual program 
    listing, NIH invites readers to direct questions to the information 
    address above about whether individual programs listed in the Catalog 
    of Federal Domestic Assistance are affected.
    
        Effective Date: June 24, 1994.
    Harold Varmus,
    Director, National Institutes of Health.
    [FR Doc. 94-16199 Filed 7-1-94; 8:45 am]
    BILLING CODE 4140-01-P
    
    
    

Document Information

Published:
07/05/1994
Entry Type:
Uncategorized Document
Action:
Notice of actions under the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines).
Document Number:
94-16199
Dates:
June 24, 1994. Harold Varmus, Director, National Institutes of Health. [FR Doc. 94-16199 Filed 7-1-94; 8:45 am] BILLING CODE 4140-01-P
Pages:
0-0 (1 pages)
Docket Numbers:
Federal Register: July 5, 1994